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ABSTRACT 
MicroRNAs (miRNAs) are a class of ~22 nt short, non-coding RNAs that post-
transcriptionally regulate target mRNA expression. To date, ~2,000 mature 
miRNAs have been identified in humans and they are estimated to regulate 
about 50% of human genes. miRNAs, due to their ubiquitous target distribution, 
contribute to diverse processes including cell development, proliferation, 
differentiation, apoptosis, and metabolism. Dysregulation of miRNA expression 
has been reported in various cancers and metabolic disorders. miRNA are also 
implicated in the initiation and progression of those diseases. In my dissertation, I 
studied the differentially expressed (DE) miRNAs upon prostaglandin E2 (PGE2) 
stimulation in prostate cancer cells (PC-3). Concurrently I examined mRNA 
expression profile of the PC-3 system and determined anticorrelated 
miRNA:mRNA pairs. The DE miRNAs and their putative targets were affected by 
the induction of PGE2. They were suggested to be involved in PGE2 
dysregulated signaling pathways in PC-3 prostate cancer. In the second part of 
the thesis work, I identified a set of adipose-enriched miRNAs from porcine 
tissues samples and verified that these miRNAs were conserved in humans. 
Adipose-enriched miRNAs were reported to be involved in metabolism, 
  
vi
inflammation responses, and tumorigenesis. The analysis results of my thesis 
experiments suggested adipose-enriched miRNAs may have a potential role in 
connecting obesity, inflammation, and cancer. It is hoped that the understanding 
of the molecular basis in cancer and metabolic disorders on the miRNA level will 
provide new diagnostic targets and therapeutic targets for the diseases.  
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1.1 Eukaryotic transcriptome 
 
  1.1.1 Eukaryotic transcriptome 
 
Upon the development of current technology, we broaden our knowledge from 
protein-coding RNA to transcriptome: the entire transcripts in a cell (1). A 
transcriptome consists of two major categories of RNA transcripts: messenger 
RNAs (mRNAs), which are transcribed from protein-coding genes and will further 
determine the sequences of amino acids in coded proteins, and non-coding 
RNAs (ncRNAs), which can not be translated into proteins, such as ribosomal 
RNAs (rRNAs), transfer RNAs (tRNAs), microRNAs (miRNAs), small nuclear 
RNAs (snRNAs), small nucleolar RNAs (snoRNAs), PIWI-interacting RNAs 
(piRNAs), and long non-coding RNAs (lncRNAs). Notably, protein-coding 
genomic regions and protein-coding transcripts only account for less than 1.5% 
to 2% of the whole genome or 5% of the transcriptome.  A significant portion of 
genome and transcriptome  (>98% and 95%, respectively) are non-coding 
genomic region or ncRNAs (2). Recent studies have revealed the crucial role of 
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ncRNAs in various aspects of cellular processes including development, 
proliferation, apoptosis, angiogenesis, immune responses, etc. (2).  
 
  1.1.2 mRNA, tRNA, and rRNA 
 
mRNAs are RNA transcripts which encode protein products. mRNAs are 
transcribed from protein-coding regions of the genome (genes). The human 
genome contains around 23,000 to 25,000 genes identified by the Human 
Genome Project (www.ornl.gov/sci/techresources/Human_Genome/home.shtml). 
After transcription, mRNAs will go through several processing steps, including 5' 
cap addition, splicing, editing, and 3' polyadenylation, before they become 
mature and ready to be transported into cytoplasm where they are translated into 
proteins. The genetic information carried by mRNAs is encoded into codons 
consisting of three bases each. Codons determine amino acid sequences in the 
protein products during the translation step.  
 
The process of translation also requires two classes of non-coding RNAs: tRNAs 
which recognize codons and transport corresponding amino acids to be 
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incorporated into the polypeptide chains, and rRNAs which comprise the protein 
synthesis machinery (3).  
 
  1.1.3 Other ncRNAs 
 
ncRNAs directly function as structural, catalytic, or regulatory RNAs, instead of 
being designated to carry genetic "blueprint". In this dissertation, I will focus on 
one class of ncRNAs which is called miRNAs. They post-transcriptionally 
regulate target mRNA expression by complementary binding to their 3'-
untranslated regions (3'-UTRs). The biogenesis and functional mechanism of 
miRNAs will be discussed later.  Besides miRNAs, which are the most widely 
studied class of ncRNAs, several other classes of ncRNAs have emerged 
including snRNAs, snoRNAs, piRNAs, and lncRNAs (2). 
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   1.1.3a snRNAs  
 
snRNAs are small, highly abundant, and uridine-rich non-coding RNAs in the 
nucleoplasm (4) which are about 150 nt in length. They include U6, U4, and U2, 
which complex with small nuclear ribonucleoproteins (snRNPs) and are involved 
in RNA splicing, in the activity of RNA polymerase II and transcription factor, and 
in maintaining the telomeres (4).  
 
   1.1.3b snoRNAs  
 
A large group of snRNAs are known as snoRNAs. They are enriched in nucleolus, 
which is the nuclear compartment where ribosomal RNAs are transcribed and 
assembled. snoRNAs have average lengths between 60 and 300 nt. They, 
together with corresponding protein partners, comprise the small nucleolar 
ribonucleoproteins (snoRNPs), which mainly function in rRNA modification 
including sequence-specific 2'-O-methylation and pseudouridylation. In addition 
to rRNA, snoRNAs are determined to post-transcriptionally modify other 
structural RNAs such as tRNAs and snRNAs (2, 3).  
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1.1.3c piRNAs 
 
piRNAs are RNAs that associate with the PIWI subfamily of Argonaute family 
proteins and are of 24-30 nt in length. Argonaute family proteins are the prime 
components of RNA-induced silencing complexes (RISCs), which silence their 
targets either by cleavage and degradation or by translational inhibition. 
Argonaute family can be divided into Ago and PIWI subfamilies. Among them, 
Ago is expressed ubiquitously while PIWI is expressed within germline cells and 
stem cells. piRNAs and PIWI proteins function to suppress the expression of 
transposable elements in germline cells or impair their mobilization. Additionally, 
recent findings also revealed their role in regulation of DNA methylation on 
epigenetic level (2, 5).  
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   1.1.3d lncRNAs 
 
lncRNAs are non-coding RNAs with length larger than 200 nt and are identified 
as the largest family of ncRNAs. lncRNA dysregulation has been determined in 
various diseases including cancer. They are able to mediate DNA methylation by 
recruiting chromatin-remodeling complexes in a temporal and spatial specific 
manner. One example to demonstrate the role of lncRNAs is their regulation of 
X-chromosome inactivation in mammals. X-inactivation specific transcript (XIST), 
a 17kb lncRNA, recruits polycomb complex to silence one of the two X 
chromosomes in females (2). Meanwhile, TSIX, a complementary form of XIST, 
regulate XIST expression during this process. lncRNAs have emerged as a 
newly highlighted target for biomarker discovery and therapeutic interventions (2, 
6).   
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1.2 miRNA 
 
  1.2.1 miRNA biogenesis and function 
 
miRNAs are a class of ~22 nt long, non-coding RNAs that post-transcriptionally 
regulate target messenger RNA (mRNA) expression by binding to their 3'-UTRs 
(7). miRNAs are first transcribed from genomic DNA by RNA polymerase II as 
primary miRNAs (pri-miRNAs), which are usually long sequences with the 5’ end 
capped and the 3’ end polyadenylated. These pri-miRNAs are cleaved into 
approximately 60-70 nt precursors (pre-miRNAs) with a 5’ phosphate and a two-
nucleotide 3’ overhang. Next, exportin-5 transports the pre-miRNAs, via a Ran-
GTP-dependent mechanism, from the nucleus to the cytoplasm where pre-
miRNAs are further processed into short double strand miRNA: miRNA* 
duplexes by the endonuclease Dicer. Mature miRNA sequences form when a 
helicase unwinds the miRNA: miRNA* duplex. Both miRNAs and miRNA*s are 
integrated into the RISCs; however, the non-functional miRNA*s are presumably 
degraded (8).  
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miRNA in the context of RISCs has the ability to complementarily pair with 3’-
UTR of its target mRNA through miRNA “seed” region (typically the eight 
nucleotides from the second site of 5’ end). The pair binding will down-regulate 
target mRNA expression either through transcript degradation or through 
translational inhibition (8). 
 
Since its first discovery in Caenorhabditis elegans in 1993 by Victor Ambros and 
colleagues, about 2,000 miRNAs have been estimated in the human genome 
according to mirBase version 18.0 (accessed January 2012) and they are 
expected to pair and regulate a significant portion (higher than 50%) of all 
protein-coding genes (9). Profiling studies of miRNAs and client mRNAs suggest 
that miRNAs contribute dramatically to cellular and developmental processes 
such as cell cycle regulation, cell proliferation, differentiation, and apoptosis.  
 
  1.2.2 miRNA detection and profiling 
 
Based on their significant role in biological functions and cellular processes, 
miRNA detection and profiling is drawing remarkable attention. Northern blot was 
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the first described method for miRNA detection. Its major limitations are RNA 
degradation, low sensitivity, low throughput, high time consumption (10), and that 
it requires previous knowledge of the miRNA sequence (11).  
 
Three major approaches which are well established currently include: 
quantitative reverse transcription PCR (qRT-PCR), miRNA microarray, and 
miRNA sequencing (miRNA-seq) (11). For the miRNA qRT-PCR approach, in 
order to overcome the lack of a common sequence for reverse transcription 
primer binding, there are two commercially available strategies: one is enzymatic 
polyadenylation at 3' end of miRNAs, and the other is ligation of a universal 
sequence as primer binding site in reverse transcription step. The advantage of 
qRT-PCR is its sensitivity, specificity, and absolute quantification, while the major 
drawback is its low to medium throughput capacity and lack of ability for novel 
sequence discovery.  
 
Microarray technology enables parallel analysis of large numbers of miRNAs on 
a single platform. To date, various approaches have been developed to prepare 
miRNA samples which will be subject to microarray detection and profiling. The 
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approach I used in my dissertation is based on a platform developed by LC 
Sciences. Its principal sample preparation steps include enzymatically catalyzed 
ligation of a short oligonucleotide to the 3'-OH end of miRNA using T4 RNA 
ligase. This is followed by hybridization to the array and staining with fluorophore-
conjugated oligonucleotides that will specifically bind to the ligated short oligo. 
miRNA microarray has the advantage on the cost and time-consumed per 
sample. Limitations include non-specific hybridization, non-uniformed ligation 
during sample preparation, difficulty to use for absolute quantification, and the 
requirement of known miRNA sequences (11).  
 
Recently developed next-generation sequencing (NGS) enables detection of both 
novel and known miRNAs as well as precise determination of miRNA sequences. 
For instance, NGS is able to distinguish isoform sequences of miRNAs which 
differ by one single nucleotide. Major limitations with NGS are its high cost and 
great request of computational aid for data analysis. Besides that, it also has 
sequence bias/preference related to enzymatic steps in small RNA cDNA library 
preparation process and mutations introduced by PCR amplification of the library 
(11). 
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The three major NGS technology providers are Roche/454, Solid from Applied 
Biosystems and Illumina. The NGS technology I applied in this dissertation was 
the Illumina platform. The pipeline of this platform includes preparation of small 
RNA cDNA library and subsequent massively parallel sequencing of it. Data 
obtained from this platform are further filtered and processed into copy number of 
each sequenced sequence (sequ-seqs). However, this copy number cannot be 
used for absolute quantification of a particular miRNA because its measurement 
is not independent of other miRNAs. One common approach to represent the 
abundance of a specific miRNA in a sample is to calculate the percentage of its 
reads to total reads (or total mappable reads). It is important to carefully examine 
the frequency distribution of miRNA reads between samples. If the distributions 
are at high variance, absolute quantification is not reliable (11).  
 
miRNA detection and profiling let us determine the differentially expressed (DE) 
miRNAs between samples of our interest. NGS also allows us to explore the 
novel miRNAs in poorly studied organisms. This is the first step of miRNA 
quantification and functional annotation.  
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  1.2.3 miRNA and diseases 
 
miRNAs are so widely involved in biological progressions that miRNA 
dysregulation is a common feature in cancer. Based on previous studies, 
miRNAs can be functionally categorized as oncogenes or tumor suppressors. For 
example, mammalian let-7 miRNAs, in particular let-7a-2, let-7c, and let-7g, 
negative regulate the human proto-oncogene RAS. Down-regulation of let-7 
family in lung cancers subsequently leads to aberrant cell proliferation. In this 
case, members of the the let-7 miRNA family act as tumor suppressor. 
Conversely, miR-221 and miR-222 can act as oncogenes by targeting the CDK 
inhibitor P27kip1 and disrupting cell cycle restriction (9).  
 
In addition to cancer, miRNAs are involved in metabolic disorders such as type 2 
diabetes, obesity, and glucose resistance. For example, miR-103/107 mediates 
insulin sensitivity and controls glucose homeostasis in mouse liver (12). miR-122, 
which is the most prevalent miRNA in liver and is conserved among multiple 
species, controls cholesterol accumulation in mouse liver (13). miR-143 regulates 
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lipid metabolism and its expression in liver is induced by obesity. Upregulated 
miR-143 impairs glucose homeostasis (14). miR-375 also mediates glucose 
regulation of insulin gene expression and β cell growth in the pancreas (15).  
 
Aberrant expression of miRNAs is regulated by transcription factors with the 
same mechanism as protein-coding mRNAs. One well-reported reciprocal 
relationship is between miR-200 family and zinc finger E-box-binding homeobox 
1 (ZEB1). ZEB1 is a transcription repressor which negatively regulates 
expression of the miR-200 family. In turn, miR-200 is also negatively targeting 
and regulating ZEB1 (16). Discovery of disease-specific miRNA signatures and 
the identification of miRNA targets, regulatory pathways, and related functions 
will benefit miRNA-based early diagnosis and therapy.  
 
In my dissertation, I set to explore miRNA profiles and their functional 
implications under specific biological conditions of our interest. Chapter 2 
described miRNAs that had been altered in prostate cancer cell line (PC-3) by 
endogenous induction of prostaglandin E2 (PGE2). We also profiled mRNAs 
within the same samples and performed miRNA;mRNA anticorrelation analysis. 
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Based on the miRNA and mRNA profile analysis, we proposed that PGE2-ZEB1-
miR-200b-PLCG1 may represent one crucial axis underlying the mechanism of 
PGE2 in prostate cancer development and progression. In Chapter 3, I focused 
on adipose miRNAs and found them to be implied in obesity, inflammation, and 
last but not least, cancer. I systematically screened profiles of six types of 
adipose tissues and two types of muscle tissues obtained from pigs. From them, 
I determined a set of adipose-enriched miRNAs that were of high abundance 
only in porcine adipose tissues. Adipose-enriched miRNAs were reported to be 
associated with metabolism, inflammatory responses, and oncogenesis in 
various types of cells by previous literatures. Additionally, our miRNA pathway 
enrichment analysis revealed that abundant miRNAs in adipose tissues and in 
human breast cancer cells shared a great portion of enriched KEGG pathways. 
Our findings provided potential miRNA-biomarkers for prediction and prevention 
of obesity and inflammation. Our analysis results suggested adipose-enriched 
miRNAs may have a role in connecting obesity, inflammation, and cancer.  
 
Taken together, my dissertation focused on miRNA profiling and in silico analysis.  
Elucidation of their specific profiles and functions will complement our 
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understanding of non-coding RNAs and the whole eukaryotic transcriptome. 
miRNA-based investigation and therapy development have gained increased 
attention. Although there are many hurdles to overcome, early clinical results 
shed light on our way to success. 
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Profiles Revealed a Novel Regulatory Mechanism of 
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2.1 Key words 
 
prostaglandin E2 (PGE2), microRNA (miRNA), gene expression, integrative 
analysis, pathway, prostate cancer 
 
2.2 Abstract 
 
Prostaglandin E2 (PGE2), a 20-carbon lipid-signaling molecule, is synthesized 
from arachidonic acid (AA) by cyclooxygenase (COX) enzymes and PGE2 
synthase enzymes (PGES). In the PGE2 autocrine loop, PGE2 interacts with the 
E-prostanoid receptors, EP1-4, and regulates subsequent signaling pathways. 
Those pathways contribute to tumorigenesis and progression via induction of cell 
proliferation, angiogenesis, invasion, and suppression of cell apoptosis. In this 
study, we investigated microRNAs (miRNAs) whose expression was disturbed by 
PGE2 using a prostate cancer cell line (PC-3) which stably expresses COX-2-
10aa-mPGES-1 (PC-3/PGE2), a novel engineered enzyme that directly and 
efficiently converts AA to PGE2. Concurrently, we profiled mRNA expression 
within the same samples and performed an integrative miRNA:mRNA analysis. 
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Through this analysis, we identified significant downregulation of miR-200a and 
miR-200b in the PC-3/PGE2 cells, and proposed this to be a result of ZEB1 
elevation. One putative downstream target of miR-200b is PLCG1, whose 
expression was upregulated in PC-3/PGE2 cells. Increase in PLCG1 expression 
activates PI3K/Akt and MAPK pathways and thereby stimulates cell proliferation, 
survival, and migration. Our study identified a group of miRNA:mRNA pairs 
whose expression profiles were coherently changed by induction of PGE2 in 
prostate cancer. Thus, these miRNA:mRNA pairs might be involved in PGE2-
related alteration of gene expression, cell function, and signaling pathways. 
These miRNAs may also serve as potential therapeutic targets for the treatment 
of PGE2-associated cancer and inflammation.  
 
2.3 Introduction 
 
Prostaglandins (PGs), whose members include prostaglandin E2 (PGE2), 
prostaglandin D2 (PGD2), and prostaglandin F2 alpha (PGF2α), are bioactive 
lipids produced by the catalyzation of cyclooxygenases (COXs) and PG 
synthases on arachidonic acid (AA) (17-19). Once exported to the 
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microenvironment, PGs bind to G-protein-coupled receptors in an autocrine or 
paracrine manner (19). PGs were first discovered and isolated from human 
seminal vesicles, and were later found to be produced in nearly all tissues of 
human body. They mediate a wide range of physiological and cellular processes 
such as control of blood pressure, contraction of smooth muscle, inflammation, 
and cancer progression (20).  
 
Among members of prostaglandins, PGE2 is commonly and ubiquitously 
produced in various types of cancer. More importantly, it is the most abundant 
PG found in prostate cancer (21, 22). PGE2 is produced from AA by COXs: 
COX-1 and COX-2, and subsequent PGE2 synthase enzymes (PGES), such as 
microsomal prostaglandin E2 synthase (mPGES-1, mPGES-2) and cytosolic 
prostaglandin E2 synthase (cPGES). COX-1 is constitutively expressed in many 
tissues, whereas COX-2 and mPGES-1 are both inducible in response to 
extracellular pro-inflammatory stimuli such as cytokines and growth factors (17, 
18, 21-25). Therefore, once the expression of COX-2 and mPGES-1 are 
triggered by pro-inflammatory signals, they will enhance the production of their 
major downstream metabolite, PGE2.  
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PGE2 functions as a pro-inflammatory factor by interacting with its EP1-4 
receptors, and thereby participates in the regulation of downstream signaling 
pathways in proliferation, angiogenesis, invasion, and suppression of apoptosis 
(17). Thus aberrant biosynthesis of PGE2 will not only cause inflammation but 
also contribute to cancer development and progression (17, 18, 21).  
 
Although extensive investigations had been carried out to study the molecular 
basis of PGE2, to date there are no reports elucidating changes in miRNA 
profiles in prostate cells over-producing PGE2 or identifying anticorrelated 
mRNAs. Instead of manipulating exogenous synthetic PGE2 level in PC-3 cells, 
we applied a novel engineered hybrid enzyme COX-2-10aa-mPGES-1, which 
can directly and efficiently convert endogenous AA into PGE2 (28). Our results 
indicated that elevation of endogenous PGE2 level directly or indirectly 
dysregulated a group of miRNAs that could potentially perturb their target mRNA 
expression and corresponding cellular signaling pathways. These pathways were 
implied in acceleration of tumor growth, invasion, and inhibition of apoptosis. 
Simultaneous survey of miRNA and mRNA profiles in the same sample provided 
a promising way to assess the inversely correlated miRNA:mRNA pairs (29-31), 
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which helped us to better understand the role of miRNAs and their interplay with 
putative target gene expression in the prostaglandin pathway in prostate cancer.  
 
2.4 Materials and methods 
 
  2.4.1 Materials 
 
Media, Geneticin (G418), Lipofectamine 2000, Alexa Fluor® 3 dyes, SuperScript 
Indirect RNA Amplification System, and NCodeTM EXPRESS SYBR® GreenERTM 
miRNA kits were purchased from Invitrogen (Carlsbad, CA). FBS was purchased 
from Sigma (St. Louis, MO). An mirVanaTM miRNA isolation kit was purchased 
from Ambion (Austin, TX). Antarctic phosphatase was purchased from New 
England Biolabs (Ipswich, MA). An RNeasy MiniElute Cleanup Kit was 
purchased from Qiagen (Valencia, CA). PCR primers were purchased from IDT 
(Coralville, IA). CyDye reactive dye was purchased from GE healthcare 
(Piscataway, NJ). Protease inhibitor cocktail and phosphatase inhibitor cocktail 
were purchased from Roche (Indianapolis, IN). DC protein assay and 
chromogenic peroxidase substrates were purchased from Bio-Rad (Hercules, 
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CA). Total PLCG1 rabbit polyclonal antibodies and anti-rabbit HRP-linked IgG 
were purchased from Cell Signaling (Beverly, MA). An MTT cell proliferation 
assay kit was purchased from ATCC (Manassas, VA). Oligonucleotide adaptor, 
hybridization station, and miRNA washing buffer were obtained from LC 
Sciences (Houston, TX).  
 
  2.4.2 Cell culture  
 
Human prostate cancer cell line PC-3 was obtained from the American Type 
Culture Collection (ATCC) and was maintained in RPMI 1640 medium (GIBCO) 
supplemented with 10% fetal bovine serum (FBS, Sigma) and 1% 
penicillin/streptomycin at 37ºC with 5% CO2.  
 
  2.4.3 Expression of the hybrid enzyme in PC-3 cells 
 
PC-3 cells were cultured to ~80% confluence and transfected with COX-2-10aa-
mPGES-1 plasmid cDNA (PC-3/PGE2) or transfected with pcDNA 3.1 vector 
alone (control PC-3) using the Lipofectamine 2000 method by following 
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manufacturer’s instructions (Invitrogen). To enable stable expression, the 
transfected cells were grown with medium containing 1% geneticin (G418). 
Constant expression of the engineered enzyme in PC-3 cells was confirmed by 
western blot (Figure 2.1). The endogenous level of PGE2 in PC-3 cells was 
determined using HPLC method in Dr. Ke-he Ruan's lab.  
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Figure 2.1: Western blots validation of hybrid enzyme COX-2-10aa-mPGES-1 
expression in PC-3 cells.   
Stable expression of COX-2-10aa-mPGES-1 in PC-3 cells after plasmid cDNA 
transfection was verified by western blots. Lane 1 was purified COX-2-10aa-mPGES-1 
enzyme. Lane 2 was control PC-3 cells transfected with pcDNA 3.1 vector (control PC-3). 
Lane 3 was PC-3 cells transfected with COX-2-10aa-mPGES-1 plasmid and cultured in 
media containing 1% geneticin (G418). Experiments were repeated 3 times.  
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  2.4.4 Total RNA extraction 
 
Total RNA from PC-3/PGE2 and control PC-3 cells was extracted and purified 
with the mirVanaTM miRNA isolation kit (Ambion) which enabled isolation of both 
miRNA and mRNA from the same sample. RNA concentration was determined 
by a NanoDrop ND-1000 spectrophotometer (Nano Drop) and RNA integrity was 
evaluated by an Agilent 2100 Bioanalyzer (Agilent Technologies). 
 
  2.4.5 miRNA expression profiling 
 
Total RNA (~0.5 µg) was 3’ dephosphorylated by Antarctic phosphatase to 
provide 3'-OH for ligation (New England Biolabs) and purified by RNeasy 
MiniElute Cleanup Kit (Qiagen). First, a specific oligonucleotide adaptor (LC 
Sciences) was ligated to the 3’ of RNA for subsequent fluorescent dendrimer-dye 
conjugation. Then tagged RNA samples were hybridized on a μParaflo 
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microfluidic chip at 40 °C for 16 hours using a micro-circulation hybridization 
station (LC Sciences). Finally, Alexa Fluor® 3 dye conjugated with dentrimer 
(Invitrogen) was circulated to the sample for staining at 34 °C for 2 hours. The 
miRNA array was washed with washing buffer (LC Sciences) at 40°C for 20 min. 
Array images were acquired on a GenePix 4400B laser scanner (Molecular 
Device) in the 532 nm channel. For both control PC-3 cells and PC-3/PGE2 cells, 
miRNA microarray profiling were carried out on three biological replicates.  
 
  2.4.6 miRNA data analysis 
 
Images were first digitalized with Array-Pro Analyzer (MediaCybernetics) to 
obtain signal mean and standard deviation of each probe spot on the array 
surface. Microarray data were further processed by background subtraction and 
LOWESS (Locally-weighted Regression) normalization so that biological 
variations between samples were identified. Differentially expressed (DE) 
miRNAs of PC-3/PGE2 cells versus control PC-3 cells were determined by t-test 
with p-value < 0.05 and fold change (FC) > 2. Heatmap and clustering of DE 
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miRNAs based on euclidean distance were generated by MeV software (The 
Institute for Genome Research).  
 
2.4.7 mRNA probe design and probe selection 
 
Candidate mRNAs were obtained from 4532 cancer-related genes collected from 
various databases. They were further classified by gene ontology (GO) 
enrichment analysis to explore their biological functions 
(http://www.geneontology.org/) (32). Genes from 11 major GO categories, such 
as cytokine, inflammation and receptor were selected for probe design and their 
corresponding mRNA sequences were obtained from NCBI 
(http://www.ncbi.nlm.nih.gov/). An in-house developed software probe design 
pipeline was employed to optimize probe performance parameters, including: 
probe length, melting temperature, CG percentage, and sequence complexity 
(lower homologous sequence content). The pipeline also refined the sequence in 
the complementary region of the target mRNA to ensure both the sensitivity and 
specificity of the probes.  Final microarray layout consisted of probes for 1001 
unique experimental sequences representing a comprehensive repertoire of 
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pivotal pathway genes and 125 house-keeping genes. Each specific sequence 
was represented 3 times on the array to ensure even hybridization and to monitor 
quality of microarray synthesis.  
 
  2.4.8 mRNA expression profiling 
 
Total RNA from PC-3 cells and PC-3/PGE2 cells were isolated and purified. Both 
cells were processed in biological triplicate. Then RNA was in vitro transcribed 
and amplified into aminoallyl-labeled antisense RNA (aa-aRNA) using 
SuperScript Indirect RNA Amplification System (Invitrogen). The aa-aRNA was 
coupled to CyDye (Cy3/Cy5, GE healthcare) reactive dye for labeling prior to 
hybridization. CyDye-aRNA was hybridized to customized mRNA microarray 
when circulating at 40 °C for 16 hours within a hybridization station (LC 
Sciences). Cy3 samples were pooled with Cy5 samples before hybridizing to the 
same array. Array was scanned with a GenePix 4400B laser scanner (Molecular 
Device) in 532nm (Cy3) channel and 635nm (Cy5) channel respectively.  
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  2.4.9 mRNA data analysis 
 
Images were first digitalized with Array-Pro Analyzer (MediaCybernetics) to 
obtain signal mean and standard deviation of each probe spot on the array 
surface. mRNA expression data processing involves background correction and 
normalized to house-keeping genes. There were totally 25 house-keeping genes 
on the array and each of them had 5 probes to detect different positions of their 
transcripts. mRNAs with low expression level which is close to background were 
disqualified from further analysis. DE mRNAs were obtained by performing 
Student’s t-test between PC-3/PGE2 cells and control PC-3 cells with a p-value < 
0.10 and FC > 1.20 or < 0.80. 
 
  2.4.10 qRT-PCR 
 
DE miRNAs and mRNAs determined from microarray profiling were validated by 
qRT-PCR using NCodeTM EXPRESS SYBR® GreenERTM miRNA kit (Invitrogen) 
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on an ABI 7900HT instrument (Applied Biosystems) following manufacturers’ 
protocols. Sequences of all the primers employed in this study were provided in 
Table 2.1. The ∆∆Ct method was applied to calculate FCs of the surveyed 
miRNAs and mRNAs. The relative FCs were plotted and error bar indicated 
standard error of mean (SEM) from three biological replicates. Significance of 
differences between PC-3 and PC-3/PGE2 cells was calculated by two-tailed 
Student's t-test.  
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Table 2.1: Primers used in qRT-PCR reactions 
miRNA Primer (5' to 3') 
hsa-miR-17 CAAAGTGCTTACAGTGCAGG 
hsa-miR-21 TAGCTTATCAGACTGATGTTGA 
hsa-miR-26a GATTTCAAGTAATCCAGGATAGGCT  
hsa-miR-26b TTCAAGTAATTCAGGATAG 
hsa-miR-146a TGAGAACTGAATTCCATGGGTT   
hsa-miR-148 GCTCAGTGCACTACAGAACTTTGT  
hsa-miR-193a GCGGGCGAGATGAAAAA   
hsa-miR-200a CGTAACACTGTCTGGTAACGATGT  
hsa-miR-200b GGTAATACTGCCTGGTAATGATGA  
hsa-miR-375 CGGCTCGCGTGAAAAA   
U6 CGCAAGGATGACACGCAAATTCGT 
RNU48 AGTGATGATGACCCCAGGTAACTC  
 
mRNA Forward Primer (5' to 3') Reverse Primer (5' to 3') 
ABL2 AAAGCTACGAGTCCTTGGTTACA GCCCATTCTTAGAGCGAACTTCA
CBL TAGGCGAAACCTAACCAAACTG AGAGTCCACTTGGAAAGATTCCT
CRK GGAGACATCTTGAGAATCCGGG GCATTCCACCACTGCTCTTC 
CRKL CTGTCGGTGTCCGAGAACTC TGGTCCCCGATCTTAAAACGG 
JAK1 AGCTCTGGTATGCTCCAAATCG GGACATCTTGTCATCAACGGTG 
MEF2C CTGGTGTAACACATCGACCTC GATTGCCATACCCGTTCCCT 
MKNK2 CCAGCCGAACTTCAGGGTTT GGTTCTGCCCCTTGAACGAA 
VEGFA TTATGCGGATCAAACCTCACC GAAGCTCATCTCTCCTATGTGC 
ZEB1 GTGACGCAGTCTGGGTGTAA GTCGCCCATTCACAGGTATC 
PLCG1 GTGTCCCTTCCTGAGTTCCA GGAGGAAGCTGAGCATGAAC 
DAG1 TCGAGTGACCATTCCAACAGA CCTGCCGCTGATACCTTGA 
MAP2K1 CTGCATGAGTGCAACTCTCC GCTGTAGAACGCACCATAGAAG 
MAP3K3 ACCGGATGCCTGGATATGAGA TGAGTGACCTGTGTCTTTGTTCT 
MAP4K4 GAAATGGCACCTATGGACAAGT GCCAACTGACCCGTTTTAACA 
PIK3C2A AAATGGGACCAGTAGTTTGCC GGGTTTGTGCGGTGATTGGTA 
GAPDH AATCCCATCACCATCTTCCA CAGAGGGGGCAGAGATGAT 
β-actin TGGGACGACATGGAGAAAAT CAGAGGCGTACAGGGATAGC 
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  2.4.11 miRNA target prediction 
 
Putative miRNA target genes of the DE miRNAs were analyzed using 
TargetScan Human 6.2 (http://www.targetscan.org) (33). TargetScan predicts the 
target genes of individual miRNA by searching the 3'-UTR of the mRNAs and 
determining whether they have the conserved match with the "seed" (2-7 
nucleotides from 5') of miRNA in 5 genomes (human, mouse, rat, dog, and 
chicken). It also emphasizes the presence of either a conserved anchoring A, 
which is an A nucleotide downstream of the seed match on 3'-UTR of mRNA or a 
m8-t8 match, which is an A: U or G: C match between the eighth nucleotide from 
5’ of the miRNA and its mRNA target.  
 
  2.4.12 Pathway analysis of DE miRNAs 
 
To elucidate the enriched biological pathways in-depth and further unravel the 
global function of a large number of genes, either DE mRNAs or predicted target 
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genes of DE miRNAs identified from the study were submitted to DAVID 
bioinformatics resources (http://david.abcc.ncifcrf.gov) (34), a freely accessible 
biological database and integrative analytic tool. First, the gene list was uploaded 
and identifier type was selected coordinately. For instance, in our case, we 
uploaded gene list with identifiers as "official gene symbol". Then, appropriate 
species where the gene list originated was indicated. Eventually, the gene list 
was condensed into gene functional groups and incorporated into KEGG 
signaling pathways (http://www.genome.jp/kegg) (35-37). The significance of 
each functional group or pathway was evaluated by Fisher's exact test and 
represented by p-value.  
 
  2.4.13 Western blots 
 
PC-3/PGE2 cells and control PC-3 cells were harvested and lysed in lysis buffer 
(20 mM Tris pH 6.8, 150 mM NaCl, 1% Triton X-100, 5% Glycerol, 2.5 mM 
sodium orthovanadate, 1x protease inhibitor cocktail (Roche) and 1x 
phosphatase inhibitor cocktail (Roche)) for 1 hour on ice. Cell lysates were 
collected by centrifuging at 13,000g for 20 min at 4 °C. Protein concentration was 
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estimated by DC protein assay (Bio-Rad). Approximate 25 μg of whole protein 
lysates were loaded into a 10% SDS-polyacrylamide gel and separated by 
electrophoresis at 110 V for 110 min. Protein were then transferred onto a PVDF 
membrane at 90 V for 90 min on ice. After transfer, membranes were block with 
5% nonfat dry milk in 1x TBST (50 mM Tris pH 7.5, 150 mM NaCl, 0.1% Tween-
20) at room temperature for 1 hour. Proteins to be examined were probed by 
corresponding specific primary antibodies in 1x TBST with 5% dry milk overnight 
at 4 °C. After washing, the blots were incubated with appropriate secondary 
antibodies which are peroxidase conjugated for 1 hour at room temperature in 
TBST with 5% dry milk. Immunoreactive proteins recognized by particular 
primary antibodies were visualized using chromogenic peroxidase substrates 
(Bio-Rad).  
 
  2.4.14 Cell proliferation assay 
 
Both PC-3/PGE2 cells and control PC-3 cells were seeded at approximate 5,000 
cells per well with total volume of 100 μl per well in 96-well flat bottom culture 
plates and allowed to grow over night at 37°C. Cell metabolism, which can 
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indicate proliferation, was determined every day from day 1 to day 6 after cell 
attachment by MTT cell proliferation assay kit (ATCC). Briefly, on each 
experimental day, all the wells were replaced with 100 μl of fresh culture medium 
and 10 μl of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide, MTT, 
was added for a further four-hour incubation period at 37°C, during which time 
the metabolically active cells converted yellow tetrazolium salt MTT to purple 
precipitate. Once the purple crystals were clearly visible inside cells, 100 μl/ well 
of detergent was added and the plate was kept in dark at room temperature for 
over night reaction. Absorbance of colorimetric signal from each well was 
measured at 570 nm using a microtiter plate reader on the following day. The 
proliferation rate of PC-3/PGE2 cells was compared with that of control PC-3 
cells after subtracting the intensity from no-cell blank control wells. All assays 
were performed in triplicate and diagram represented average absorbance and 
standard error of mean from them.  
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2.5 Results 
 
2.5.1 Excessive endogenous PGE2 elicited differential 
expression of miRNAs 
 
The endogenous level of PGE2 in PC-3 cells was determined using HPLC 
method in Dr. Ke-he Ruan's lab. They showed that majority of AA was 
specifically converted into PGE2 in PC-3/PGE2 cells. To explore the alterations 
in miRNAs expression when the PGE2 level was induced, the miRNA profile of 
PC-3/PGE2 cells was compared with that of control PC-3 cells. In total, 1,212 
unique human mature miRNAs from miRBase version 16 were examined by 
microarray assays (27). We found that 65 miRNAs were downregulated and 34 
were upregulated with p < 0.1 after T-test in response to over-production of 
PGE2 (Table 2.2 and Table 2.3). Moreover, after refining the criteria of significant 
DE miRNAs to p < 0.05 with 2-fold cut off, 30 miRNAs were down and 18 were 
upregulated, which were used for subsequent analysis. Alternations in the 
expression of DE miRNAs and their distances (similarity) were displayed by 
conducting a Heatmap analysis with hierarchical clustering (Figure 2.2).  
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We surveyed 17 DE miRNAs along with RNU48 and U6 as endogenous controls 
by performing miRNA qRT-PCR on PC-3/PGE2 cells and control PC-3 cells to 
further validate their expression level. Nine out of 17 where significantly changed 
when confirmed using qRT-PCR (Figure 2.3) and supported the reproducibility 
and reliability of data obtained.  
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Table 2.2: miRNAs downregulated in PC-3/PGE2 cells  
Index miRNA ID Log2(FC) p-value 
1 hsa-miR-433 -18.19 1.59E-02 
2 hsa-miR-455-5p -14.96 2.64E-02 
3 hsa-miR-585 -14.81 8.01E-03 
4 hsa-miR-659 -8.35 4.78E-02 
5 hsa-miR-664* -6.37 7.85E-02 
6 hsa-miR-375 -4.82 1.79E-02 
7 hsa-miR-101 -3.57 4.73E-03 
8 hsa-miR-4324 -3.13 1.25E-03 
9 hsa-miR-1287 -2.86 1.32E-02 
10 hsa-miR-342-3p -2.74 6.83E-03 
11 hsa-miR-4252 -2.62 5.57E-02 
12 hsa-miR-454 -2.62 3.43E-02 
13 hsa-miR-200a -2.58 5.58E-03 
14 hsa-miR-223 -2.34 4.81E-02 
15 hsa-miR-4267 -2.33 2.23E-02 
16 hsa-miR-181c -2.24 8.05E-02 
17 hsa-miR-200b -2.08 2.99E-03 
18 hsa-miR-3647-3p -2.08 7.54E-03 
19 hsa-miR-26b -2.02 9.81E-04 
20 hsa-miR-148b -2.02 1.39E-02 
21 hsa-miR-21 -1.88 8.89E-03 
22 hsa-miR-652 -1.86 4.91E-03 
23 hsa-miR-195 -1.77 7.87E-02 
24 hsa-miR-3651 -1.61 6.75E-02 
25 hsa-miR-4258 -1.57 4.59E-02 
26 hsa-miR-146a -1.51 1.20E-04 
27 hsa-miR-29b-2* -1.48 9.02E-02 
28 hsa-miR-3661 -1.45 8.47E-02 
29 hsa-miR-1973 -1.44 2.01E-02 
30 hsa-miR-3647-5p -1.43 5.07E-03 
31 hsa-miR-4312 -1.38 8.58E-02 
32 hsa-miR-425* -1.35 9.20E-02 
33 hsa-miR-320e -1.31 2.66E-02 
34 hsa-miR-1180 -1.24 3.59E-02 
35 hsa-miR-181a -1.21 4.09E-02 
36 hsa-miR-424* -1.20 7.04E-02 
37 hsa-miR-4279 -1.17 5.46E-02 
38 hsa-miR-1246 -1.12 3.05E-03 
39 hsa-miR-193a-3p -1.11 9.21E-03 
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Table 2.2 (cont.) 
Index miRNA ID Log2(FC) p-value 
40 hsa-miR-3609 -1.11 1.01E-03 
41 hsa-miR-3676 -1.02 3.99E-02 
42 hsa-miR-572 -1.01 6.70E-02 
43 hsa-miR-502-3p -0.99 9.25E-02 
44 hsa-miR-140-3p -0.92 7.29E-03 
45 hsa-miR-518d-3p -0.91 6.80E-02 
46 hsa-miR-484 -0.84 2.85E-02 
47 hsa-miR-30b -0.82 5.12E-02 
48 hsa-miR-362-5p -0.81 1.48E-02 
49 hsa-miR-320b -0.81 6.08E-02 
50 hsa-miR-320d -0.75 8.59E-02 
51 hsa-miR-320c -0.73 6.14E-02 
52 hsa-miR-320a -0.69 6.02E-02 
53 hsa-miR-551b -0.67 6.93E-02 
54 hsa-miR-532-5p -0.66 3.26E-02 
55 hsa-miR-568 -0.64 9.36E-03 
56 hsa-miR-26a -0.63 4.91E-03 
57 hsa-let-7g -0.62 7.27E-02 
58 hsa-miR-636 -0.61 6.34E-03 
59 hsa-miR-500b -0.6 9.01E-02 
60 hsa-let-7b -0.56 5.64E-02 
61 hsa-miR-30d -0.52 7.85E-02 
62 hsa-miR-210 -0.35 1.14E-03 
63 hsa-let-7f -0.31 3.44E-02 
64 hsa-let-7a -0.3 2.48E-02 
65 hsa-miR-100 -0.29 2.82E-02 
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Table 2.3:  miRNAs upregulated in PC-3/PGE2 cells  
Index miRNA ID Log2(FC) p-value 
1 hsa-miR-1261 6.92 7.45E-02 
2 hsa-miR-590-5p 5.38 9.17E-02 
3 hsa-miR-498 5.33 1.83E-02 
4 hsa-miR-548m 4.11 3.86E-02 
5 hsa-miR-548h 3.60 1.29E-02 
6 hsa-miR-1469 2.99 4.13E-05 
7 hsa-miR-889 2.86 6.03E-02 
8 hsa-miR-762 2.61 3.35E-05 
9 hsa-miR-3196 1.81 2.91E-03 
10 hsa-miR-3656 1.80 3.72E-03 
11 hsa-miR-1915 1.80 1.51E-02 
12 hsa-miR-4281 1.77 4.02E-02 
13 hsa-miR-3178 1.67 3.28E-03 
14 hsa-miR-638 1.62 1.77E-02 
15 hsa-miR-3195 1.58 1.63E-03 
16 hsa-miR-3665 1.51 8.69E-04 
17 hsa-miR-663 1.46 2.53E-02 
18 hsa-miR-18a 1.34 8.34E-02 
19 hsa-miR-3190 1.20 1.36E-02 
20 hsa-miR-301a 1.17 3.99E-04 
21 hsa-miR-3141 1.13 5.26E-03 
22 hsa-miR-1280 1.01 1.13E-02 
23 hsa-miR-3679-5p 0.94 8.07E-02 
24 hsa-miR-23a 0.89 1.10E-02 
25 hsa-miR-17 0.88 1.06E-02 
26 hsa-miR-149* 0.86 5.91E-02 
27 hsa-miR-3149 0.81 6.45E-03 
28 hsa-miR-20a 0.76 1.25E-02 
29 hsa-miR-574-5p 0.75 1.43E-02 
30 hsa-miR-425 0.70 1.32E-02 
31 hsa-miR-601 0.54 3.50E-02 
32 hsa-miR-93 0.51 1.62E-02 
33 hsa-miR-23b 0.44 8.83E-02 
34 hsa-miR-361-5p 0.29 4.77E-02 
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Figure 2.2: Heatmap and hierarchical clustering of DE miRNAs in response to 
PGE2 
Each row represented a miRNA and each column a sample. Dendrograms at the top and 
on the left side indicated the euclidean distance among samples or miRNAs. Red and 
Green color denoted Z-value ranging from -1.5 to 0 to +1.5, although values at each 
maximal color may exceed that amount. Red represented high expression level which is 
above the mean and green low expression. Detailed expression and FCs of miRNAs were 
shown in Table 2.2 and Table 2.3.  
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Figure 2.3: qRT-PCR validation of selected DE miRNAs identified from miRNA 
microarray  
Quantitative of miRNA expression in PC-3/PGE2 cells and in control PC-3 cells was 
obtained by qRT-PCR. U6 and RNU48 small RNAs were applied as endogenous house-
keeping genes. The height of columns indicated FCs of miRNA expression for PC-
3/PGE2 cells versus control PC-3 cells (control FCs were  set to one). Error bars depicted 
SEM of three biological replicates. Significance of differences between PC-3 cells 
(control) and PC-3/PGE2 cells was calculated by two-tailed Student's t-test and are 
represented by p-value. *** represented a p-value < 0.001, ** represented a p-value < 
0.01, * represented a p-value < 0.05, no asterisk represented no significant differences (p-
value > 0.05).  
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  2.5.2 Target prediction and pathway enrichment analysis 
of DE miRNAs 
 
miRNAs exert their biological function mainly by altering expression level of their 
target genes. To elucidate the crucial role of a specific DE miRNA, we initially 
predicted its potential target genes with the aid of TargetScan Human 6.2 (33), 
and then conducted pathway enrichment analysis on all the target genes by 
applying DAVID bioinformatics resources (34). The number of target genes that 
had been predicted for each DE miRNA by TargetScan and the top most 
enriched KEGG pathways for the putative target genes based on DAVID pathway 
enrichment analysis were summarized in Table 2.4.  
 
Essential pathways associated with the downregulated miRNAs were pathways 
in cancer (five out of 30 miRNAs), the MAPK pathway (five out of 30 miRNAs), 
and Neurotrophin signaling pathway (three out of 30 miRNAs). Meanwhile, the 
notable pathway with respect to upregulated miRNAs was pathway in cancer 
(two out of 18 miRNAs) (Table 2.4). Intriguingly, downregulated miRNAs, (e.g., 
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miR-101, -146, -148, -181, -193, -200, -21, -26, and -375) had been studied by 
different groups and reported in previous publications; while upregulated miRNAs 
(e.g., miR-1280, -301, -3141, -3665, -498, and -548) lacked target and 
corresponding pathway information.  
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Table 2.4: Target prediction and pathway enrichment analysis of significant DE 
miRNAs in PC-3/PGE2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Italic: upregulated miRNAs in PC-3/PGE2 cells compared to control PC-3 cells 
DE miRNA ID
No. of 
conserved 
targets 
No. of targets found 
in KEGG pathways Top1 enriched KEGG pathway
No. of targets in 
Top1 enriched 
pathway 
p -value for 
Top1 
pathway
miR-101 803 213 Pathways in cancer 32 1.10E-05
miR-1180 13 7 Pancreatic cancer 2 8.20E-02
miR-1246 178 42 Neuroactive ligand-receptor interaction 7 1.60E-02
miR-1287 162 29 MAPK signaling pathway 8 4.60E-04
miR-146a 224 55 Pathways in cancer 10 7.00E-03
miR-148b 698 198 Focal adhesion 20 2.50E-04
miR-181a 1194 310 Neurotrophin signaling pathway 21 4.70E-05
miR-193a-3p 221 56 Pathways in cancer 13 1.50E-04
miR-1973 25 5
miR-200a 744 185 Pathways in cancer 26 2.70E-04
miR-200b 1057 290 Neurotrophin signaling pathway 32 7.00E-13
miR-21 307 89 MAPK signaling pathway 17 1.00E-05
miR-223 311 84 Prostate cancer 7 3.10E-03
miR-26b 885 219 Wnt signaling pathway 18 2.20E-04
miR-320e 296 75 Hypertrophic cardiomyopathy (HCM) 7 1.40E-03
miR-342-3p 282 79 Long-term potentiation 5 2.00E-02
miR-3609 865 238 Pathways in cancer 38 2.80E-07
miR-3647-3p 927 248 Ubiquitin mediated proteolysis 19 9.40E-05
miR-3647-5p 206 61 Calcium signaling pathway 7 1.70E-02
miR-3676 13 5
miR-375 229 62 Maturity onset diabetes of the young 3 3.60E-02
miR-4258 28 10 Non-small cell lung cancer 2 9.20E-02
miR-4267 442 114 MAPK signaling pathway 13 1.50E-02
miR-4324 923 236 MAPK signaling pathway 24 2.60E-03
miR-433 317 91 Oocyte meiosis 10 1.20E-04
miR-454 899 248 Endocytosis 27 6.00E-07
miR-455-5p 199 49 Adherens junction 5 5.70E-03
miR-585 5 1
miR-652 8 2
miR-659 697 175 MAPK signaling pathway 21 7.00E-04
miR-1280 88 29 Neurotrophin signaling pathway 4 3.00E-02
miR-1469 2 2
miR-1915 354 87 Pathways in cancer 12 2.10E-02
miR-301a 899 248 Endocytosis 27 6.00E-07
miR-3141 11 4 Endometrial cancer 2 3.00E-02
miR-3178 10 2
miR-3190 225 56 Lysosome 6 8.20E-03
miR-3195 5 1
miR-3196 50 12 Small cell lung cancer 3 1.30E-02
miR-3656 21 5 Cell adhesion molecules (CAMs) 2 1.00E-01
miR-3665 292 79 Axon guidance 8 3.40E-03
miR-4281 203 62 Adherens junction 6 2.10E-03
miR-498 547 136 Wnt signaling pathway 12 2.10E-03
miR-548h 659 162 Pathways in cancer 22 1.40E-03
N/A
N/A
N/A
N/A
N/A
N/A
N/A
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  2.5.3 Increased biosynthesis of PGE2 altered gene 
expression at mRNA level 
 
To assess the impact of enhanced intracellular PGE2 level in the context of gene 
expression, we systematically profiled mRNA transcripts from PC-3 and PC-
3/PGE2 cells using mRNA expression microarrays. The probe content of mRNA 
microarray was determined by analysis and clustering of 4,532 cancer-related 
genes according to gene ontology classification (32). Probes for 1,001 genes 
which belonged to cytokine, inflammation, and receptor were included in the 
array. After t-test, expression of 124 mRNAs was upregulated and 106 
downregulated upon increase of PGE2 (p-value < 0.10 and FC > 1.20 or < 0.80) 
(Table 2.5 and Table 2.6). 28 DE mRNAs were validated by qRT-PCR (Figure 
2.4) and all of them showed consistent expression with microarray results.  
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Table 2.5: mRNAs upregulated in PC-3/PGE2 cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Index Official gene symbol Accession no. FC p-value
1 C13ORF15 NM_014059 4.06 5.75E-14
2 NCF2 NM_000433 3.54 4.48E-13
3 CXCL1 NM_001511 3.32 2.63E-02
4 SGK1 NM_005627 3.19 6.46E-02
5 AKAP2 NM_007203 3.17 0.00E+00
6 SPHK1 NM_021972 3.14 0.00E+00
7 CDC6 NM_001254 3.04 2.56E-04
8 RPSA NM_002295  2.73 8.88E-16
9 DRD1 NM_000794 2.7 8.25E-08
10 TK1 NM_003258 2.59 4.82E-07
11 EPHB6 NM_004445 2.48 8.67E-06
12 CXCL6 NM_002993 2.41 9.30E-04
13 PIM2 NM_006875 2.39 2.65E-06
14 PLAU NM_002658 2.31 0.00E+00
15 TNFSF15 NM_005118 2.29 1.44E-02
16 EIF2C2 NM_012154 2.24 0.00E+00
17 DDIT3 NM_004083 2.23 0.00E+00
18 FGFR4 NM_002011 2.2 7.64E-02
19 CCNE1 NM_001238 2.12 3.85E-03
20 PIK3CD NM_005026 2.05 1.23E-11
21 CDKN1C NM_000076 1.93 0.00E+00
22 FER NM_005246 1.9 1.39E-05
23 TYRO3 NM_006293 1.89 3.47E-04
24 EPHB2 NM_004442 1.89 7.69E-02
25 CDC20 NM_001255 1.86 7.82E-08
26 CXCR4 NM_003467 1.8 4.35E-06
27 TMED7 NM_021649 1.75 4.31E-05
28 CD70 NM_001252 1.74 1.13E-03
29 EIF2C3 NM_024852 1.72 5.01E-02
30 IGF2R NM_000876 1.71 1.21E-10
31 CDKN1A NM_000389 1.69 1.26E-03
32 MKNK2 NM_017572 1.67 0.00E+00
33 MC1R NM_006086 1.66 6.50E-04
34 HK1 NM_000188 1.66 1.38E-06
35 NFYA NM_002505 1.64 2.90E-03
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Table 2.5 (cont.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Index Official gene 
symbol
Accession no. FC p-value
36 CCL26 NM_006072 1.63 7.91E-02
37 CSNK1D NM_001893 1.63 7.86E-10
38 MLH1 NM_000249 1.63 0.00E+00
39 RIPK2 NM_003821 1.62 6.00E-15
40 FUT8 NM_178157 1.61 0.00E+00
41 IFNAR2 NM_000874 1.6 1.59E-03
42 RBM3 NM_006743 1.6 6.34E-12
43 PARD3 NM_019619 1.58 4.14E-03
44 UBE2C NM_181803 1.57 0.00E+00
45 MAP3K3 NM_002401 1.56 1.20E-04
46 BMP2K NM_198892 1.56 1.60E-08
47 GDF15 NM_004864 1.54 6.78E-13
48 PTK7 NM_002821 1.53 6.28E-04
49 GSK3B NM_002093 1.53 8.13E-02
50 CDC42BPA NM_003607 1.53 4.18E-09
51 PVR NM_006505 1.53 1.04E-07
52 PLK2 NM_006622 1.52 5.61E-04
53 MVD NM_002461 1.51 9.89E-03
54 CSNK1E NM_001894 1.5 5.10E-14
55 SOCS2 NM_003877 1.5 3.65E-02
56 PRKCZ NM_002744 1.48 1.09E-09
57 CDC25B NM_004358 1.48 3.37E-07
58 LMNA NM_005572 1.48 2.78E-08
59 GPI NM_000175 1.47 4.81E-14
60 FHL1 NM_001449 1.47 0.00E+00
61 BMP8B NM_001720 1.47 8.32E-07
62 LOC344593 NM_002834 1.46 7.46E-07
63 SREBF2 NM_004599 1.46 2.33E-04
64 ACVR1 NM_001105 1.45 5.47E-07
65 PDK1 NM_002610 1.44 9.03E-02
66 ABL2 NM_005158 1.42 1.06E-03
67 HSPH1 NM_006644 1.42 1.83E-08
68 PIK3C2A NM_002645 1.42 1.83E-04
69 DLG4 NM_001365 1.42 8.20E-02
70 PAK1 NM_002576 1.42 3.19E-02
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Table 2.5 (cont.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Index Official gene 
symbol
Accession no. FC p-value
71 MAP4K4 NM_004834 1.41 0.00E+00
72 DSP NM_004415 1.4 7.93E-05
73 TNFSF14 NM_003807 1.4 5.18E-02
74 ARRB2 NM_004313 1.4 5.40E-04
73 TNFSF14 NM_003807 1.4 5.18E-02
74 ARRB2 NM_004313 1.4 5.40E-04
75 GNB2 NM_005273 1.39 7.66E-03
76 PPM1D NM_003620 1.38 6.25E-02
77 SH2B2 NM_020979 1.38 3.02E-03
78 PTTG2 NM_004219 1.37 1.27E-03
79 CDK10 NM_001098533 1.37 1.43E-06
80 E2F3 NM_001949 1.37 6.29E-03
81 CHST2 NM_004267 1.37 3.95E-02
82 IL18 NM_001562 1.36 8.87E-03
83 ADAM17 NM_003183 1.36 3.75E-04
84 GNAS NM_080425 1.36 4.25E-13
85 SLK NM_014720 1.34 2.52E-02
86 ADAM19 NM_033274 1.34 1.35E-03
87 PLCG1 NM_002660 1.34 6.34E-02
88 PPP1CA NM_002708 1.33 3.78E-03
89 PRKAR1A NM_002734 1.32 3.08E-06
90 CDKN2A NM_000077 1.32 3.64E-05
91 LOC407835 NM_030662 1.32 2.80E-02
92 CETN2 NM_004344 1.31 1.39E-04
93 INPPL1 NM_001567 1.31 7.45E-04
94 CDK4 NM_000075 1.31 1.34E-03
95 PIK3CG NM_002649 1.31 1.44E-03
96 MEF2C NM_002397 1.31 5.85E-02
97 JAK1 NM_002227 1.3 2.98E-06
98 PFKP NM_002627 1.29 1.50E-02
99 PIM1 NM_002648 1.29 6.01E-03
100 RGS19 NM_005873 1.29 2.72E-03
101 PGK1 NM_000291 1.29 6.83E-03
102 CSNK2A1 NM_001895 1.29 7.37E-03
103 ABI2 NM_005759 1.28 3.46E-02
104 SOCS6 NM_004232 1.28 9.40E-03
105 BCR NM_004327 1.28 9.90E-02
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Table 2.5 (cont.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Index Official gene 
symbol
Accession no. FC p-value
106 BAZ1B NM_032408 1.27 1.33E-02
107 CRKL NM_005207 1.26 1.71E-04
108 TCF3 NM_003200 1.26 3.16E-02
109 TSPYL2 NM_022117 1.26 4.81E-05
110 MAP2K1 NM_002755 1.25 5.39E-03
111 MADD NM_003682 1.25 7.52E-02
112 CRK NM_016823 1.25 6.12E-04
113 ILK NM_004517 1.25 1.11E-04
114 PRKACA NM_002730 1.23 5.90E-03
115 CBL NM_005188 1.23 5.11E-02
116 CDK13 NM_003718 1.23 2.02E-03
117 LOC642954 NM_005610 1.23 2.14E-02
118 CKS2 NM_001827 1.23 1.90E-03
119 DAG1 NM_004393 1.22 8.93E-02
120 SIRPA NM_080792 1.22 2.21E-02
121 BCAR3 NM_003567 1.21 8.21E-04
122 IRAK1 NM_001569 1.21 8.93E-08
123 PTPN11 NM_002834 1.2 2.41E-03
124 CXCR5 NM_001716 1.2 2.28E-02
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Table 2.6: mRNAs downregulated in PC-3/PGE2 cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Index
Official gene 
symbol Accession no. FC p-value
1 TNFSF10 NM_003810 0.07 0.00E+00
2 C4A NM_007293 0.16 4.57E-06
3 BMP3 NM_001201 0.2 2.55E-08
4 STAT1 NM_007315 0.26 1.44E-15
5 BSN NM_003458 0.3 8.57E-02
6 IL7 NM_000880 0.32 1.80E-02
7 STAT2 NM_005419 0.36 0.00E+00
8 IL1A NM_000575 0.36 4.39E-02
9 RGS2 NM_002923 0.41 0.00E+00
10 KDR NM_002253 0.45 0.00E+00
11 NR2F1 NM_005654 0.45 0.00E+00
12 VEGFA NM_003376 0.46 0.00E+00
13 KAT2B NM_003884 0.46 0.00E+00
14 BMPR1B NM_001203 0.48 0.00E+00
15 PIK3R3 NM_003629 0.49 6.04E-11
16 BRS3 NM_001727 0.49 2.00E-02
17 SH2D4A NM_022071 0.5 1.57E-02
18 IL29 NM_172140 0.5 7.55E-02
19 C5 NM_001735 0.5 0.00E+00
20 NBN NM_002485 0.51 2.16E-07
21 IFNGR1 NM_000416 0.51 2.06E-11
22 GDF11 NM_005811 0.51 2.47E-04
23 CDKN1B NM_004064 0.52 1.11E-15
24 CSNK1A1 NM_001892 0.52 0.00E+00
25 LOC651610 NM_000051 0.53 7.66E-09
26 TNFSF4 NM_003326 0.53 2.39E-02
27 ACTA1 NM_001100 0.55 8.25E-03
28 PIK3CB NM_006219 0.56 1.32E-03
29 LHCGR NM_000233 0.56 3.77E-05
30 EIF2AK2 NM_002759 0.57 1.18E-05
31 NDC80 NM_006101 0.58 6.79E-04
32 MAP2K6 NM_002758 0.59 4.47E-02
33 CABC1 NM_020247 0.59 3.06E-08
34 RCBTB1 NM_018191 0.59 7.35E-03
35 DNAJC19 NM_145261 0.6 5.80E-04
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Table 2.6 (cont.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Index Official gene symbol Accession no. FC p-value
36 SH3BP2 NM_003023 0.62 5.69E-02
37 TFDP2 NM_006286 0.62 4.49E-02
38 CLK1 NM_004071 0.62 9.39E-07
39 SPHK2 NM_020126 0.63 1.02E-02
40 PKLR NM_000298 0.63 6.80E-02
41 SHC4 NM_203349 0.63 6.82E-04
42 RBL2 NM_005611 0.64 1.89E-06
43 ERBB2 NM_004448 0.64 2.94E-03
44 LOC648152 NM_001184 0.64 7.93E-04
45 TNNI3 NM_000363 0.64 4.80E-05
46 ANAPC11 NM_001002244 0.65 8.64E-02
47 TJP1 NM_175610 0.66 0.00E+00
48 CSNK1G3 NM_004384 0.66 2.44E-02
49 CDK1 NM_001786 0.66 1.88E-04
50 CIT NM_007174 0.66 3.59E-05
51 CCNG1 NM_004060 0.67 0.00E+00
52 RPS6KA6 NM_014496 0.68 5.57E-02
53 TPM1 NM_000366 0.68 9.14E-05
54 NEK6 NM_014397 0.68 9.18E-02
55 PPP1R13B NM_015316 0.69 1.70E-02
56 NR2F2 NM_021005 0.69 4.67E-11
57 EVL NM_016337 0.7 7.28E-02
58 PRKCH NM_006255 0.7 1.22E-03
59 PRKACB NM_182948 0.7 2.74E-02
60 MAPKSP1 NM_021970 0.7 7.88E-02
61 SSSCA1 NM_006396 0.71 7.96E-05
62 CCND1 NM_053056 0.71 1.03E-10
63 CDKN2B NM_004936 0.71 1.40E-08
64 RPS6KB1 NM_003161 0.71 1.88E-04
65 STYK1 NM_018423 0.71 8.11E-02
66 PARD6B NM_032521 0.71 4.62E-02
67 SOX4 NM_003107 0.71 2.50E-05
68 SMC4 NM_005496 0.72 8.07E-04
69 DLG3 NM_021120 0.72 1.22E-04
70 ING1 NM_005537 0.72 9.30E-04
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Table 2.6 (cont.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Index
Official gene 
symbol Accession no. FC p-value
71 PIK3C2B NM_002646 0.73 1.74E-03
72 SPDYA NM_002709 0.73 1.01E-04
73 GNAO1 NM_020988 0.73 4.38E-02
74 PTP4A1 NM_003463 0.73 5.73E-03
75 CCNG2 NM_004354 0.73 4.97E-02
76 GNPTG NM_032520 0.73 7.50E-06
77 NME4 NM_005009 0.74 1.21E-04
78 LY6G5B NM_001320 0.74 1.07E-04
79 RACGAP1P NM_013277 0.74 6.84E-02
80 EPS15 NM_001981 0.74 1.77E-02
81 PRKDC NM_006904 0.74 4.39E-06
82 CCNB1 NM_031966 0.74 1.22E-03
83 KRT18P19 NM_000224 0.75 5.37E-05
84 ILF3 NM_004516 0.76 1.26E-07
85 MST1R NM_002447 0.76 8.39E-03
86 ANXA11 NM_001157 0.76 1.60E-03
87 PRKCD NM_006254 0.76 9.08E-02
88 STAT6 NM_003153 0.76 1.08E-02
89 PDK2 NM_002611 0.77 3.85E-02
90 MAP4K3 NM_003618 0.77 3.61E-05
91 AKT1 NM_005163 0.77 1.33E-03
92 CXCL5 NM_002994 0.77 4.20E-02
93 DCK NM_000788 0.78 8.47E-04
94 CALM3 NM_006888 0.78 4.37E-03
95 TSG101 NM_006292 0.78 2.88E-03
96 HK2P1 NM_000189 0.78 6.02E-06
97 IFNAR1 NM_000629 0.78 2.72E-03
98 CDKN3 NM_005192 0.79 5.77E-04
99 RASSF1 NM_007182 0.79 1.83E-06
100 REG3G NM_198448 0.79 5.11E-02
101 AHR NM_001621 0.79 1.49E-04
102 PAFAH1B1 NM_000430 0.79 5.25E-04
103 HCK NM_002110 0.79 9.05E-02
104 CTTN NM_005231 0.8 1.50E-10
105 AREGB NM_001657 0.8 7.18E-10
106 EPHB3 NM_004443 0.8 3.24E-03
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Figure 2.4: qRT-PCR validation of DE mRNAs identified from mRNA expression 
microarray  
Relative mRNA expression in PC-3/PGE2 cells and control PC-3 cells were assessed by 
qRT-PCR. GAPDH and β-actin mRNAs were used as house-keeping genes. Expression 
of target mRNAs was normalized to GAPDH. The height of columns indicated FCs of 
mRNA expression between PC-3/PGE2 cells and control PC-3 cells (control FCs were 
set to one). Error bars were SEM of three biological replicates. Significance of 
differences between PC-3 cells (control) and PC-3/PGE2 cells was calculated by two-
tailed Student's t-test and are represented by p-value. *** represented a p-value < 0.001, 
** represented a p-value < 0.01, * represented a p-value < 0.05, no asterisk represented 
no significant differences (p-value > 0.05).  
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  2.5.4 DE mRNAs were enriched in specific pathways 
 
Furthermore, we estimated the putative affected signaling pathways by DE 
mRNAs using the NIH/DAVID pathway enrichment analysis tool. All the genes in 
KEGG signaling pathways were applied as background. The significance of 
enrichment was calculated by Fisher's exact test and represented by p-value. 
Based on our results, 108 among the 124 upregulated mRNAs were 
accompanied with KEGG pathway annotation; in contrast, 72 out of 106 
downregulated mRNAs were associated with KEGG pathways (35-37). The 
upregulated mRNAs are mainly involved in the insulin signaling pathway, 
meanwhile, the downregulated mRNAs are primarily implicated in the Jak-Stat 
signaling pathway (Table 2.7 and Table 2.8).  
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Table 2.7: Pathway enrichment analysis of upregulated mRNAs in PC-3/PGE2 
according to KEGG signaling pathways  
(p-value < 0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enriched pathway Gene count p -value Genes
Insulin signaling 
pathway
16 1.90E-08
PIK3CG, PRKCZ, SOCS2, MAP2K1, PIK3CD, CBL, MKNK2, 
HK1, LOC407835, PPP1CA, CRKL, GSK3B, PRKAR1A, 
SH2B2, PRKACA, CRK
Chemokine signaling 
pathway
17 2.54E-07
CXCL1, PIK3CG, PRKCZ, PARD3, MAP2K1, PIK3CD, CXCL6, 
CCL26, CRKL, ARRB2, GNB2, CXCR5, CXCR4, GSK3B, 
PRKACA, PAK1, CRK
Neurotrophin 
signaling pathway
14 3.68E-07
PIK3CG, PDK1, IRAK1, MAP2K1, PIK3CD, LOC344593, 
PTPN11, LOC407835, CRKL, MAP3K3, PLCG1, GSK3B, 
RIPK2, SH2B2, CRK
ErbB signaling 
pathway
12 4.68E-07 PIK3CG, LOC407835, CDKN1A, CRKL, PLCG1, MAP2K1, 
GSK3B, PIK3CD, CBL, PAK1, CRK, ABL2
T cell receptor 
signaling pathway
10 1.61E-04 PDK1, PIK3CG, LOC407835, PLCG1, MAP2K1, GSK3B, 
PIK3CD, CBL, PAK1, CDK4
MAPK signaling 
pathway
14 1.25E-03
MEF2C, FGFR4, MAP2K1, MKNK2, DDIT3, CDC25B, 
LOC407835, MAP4K4, CRKL, ARRB2, MAP3K3, PRKACA, 
PAK1, CRK
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Table 2.8: Pathway enrichment analysis of downregulated mRNAs in PC-3/PGE2 
according to KEGG signaling pathways  
(p-value < 0.01) 
Enriched pathway Gene count p -value Genes
Jak-STAT signaling 
pathway 11 4.83E-05
STAT6, AKT1, CCND1, IL29, IL7, PIK3CB, PIK3R3, STAT1, 
IFNGR1, STAT2, IFNAR1
Insulin signaling 
pathway
10 9.25E-05 SPDYA, HK2P1, AKT1, PIK3CB, PKLR, CALM3, RPS6KB1, 
PRKACB, PIK3R3, SHC4
ErbB signaling 
pathway 8 1.84E-04
AKT1, CDKN1B, PIK3CB, ERBB2, RPS6KB1, AREGB, 
PIK3R3, SHC4
p53 signaling 
pathway 7 3.31E-04
LOC651610, CCNB1, CDK1, CCND1, LOC648152, CCNG1, 
CCNG2
mTOR signaling 
pathway
6 7.19E-04 AKT1, RPS6KA6, PIK3CB, VEGFA, RPS6KB1, PIK3R3
Chemokine signaling 
pathway
10 1.05E-03 AKT1, CXCL5, PIK3CB, HCK, PRKACB, PIK3R3, STAT1, 
PRKCD, STAT2, SHC4
VEGF signaling 
pathway
6 3.73E-03 AKT1, SPHK2, PIK3CB, VEGFA, PIK3R3, KDR
Neurotrophin 
signaling pathway
7 7.32E-03 AKT1, RPS6KA6, PIK3CB, CALM3, PIK3R3, PRKCD, SHC4
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  2.5.5 Integrative analysis of DE miRNA and mRNA profiles  
 
We concurrently profiled miRNA and mRNA expression level in PC-3/PGE2 cells 
and compared them with the level in PC-3 control cells. We found that increased 
biosynthesis of PGE2 largely elicited the differential expression of both miRNAs 
and mRNAs. DE mRNAs were involved in major signaling pathways, whereas 
miRNAs may potentially interact and negative regulate mRNAs of their target 
genes at post-transcriptional level. To better elucidate the putative miRNA-
mRNA-pathway framework altered by upregulation of PGE2, we identified the 
anticorrelated miRNA:mRNA pairs based on their expression profiles (Table 2.9). 
One single miRNA may target and regulate multiple genes and one gene may be 
targeted and regulated by multiple miRNAs after transcription. Our miRNA;mRNA 
integrative analysis approach determined putative miRNA:mRNA pairs which 
were altered by over-production of PGE2. miRNA target prediction was carried 
out in silico. Meanwhile, inverse correlated expression profiles between miRNA 
and their predicted targets provided another layer of evidence for their possible 
interaction. According to known pathway annotations for target mRNAs, we are 
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able to first link miRNAs to their predicted targets and then implicate miRNAs into 
pathways.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
- 61 -
Table 2.9: Anticorrelated miRNA:mRNA pairs identified by integrative microarray 
profile analysis in PC-3/PGE2 cells 
Downregulated 
miRNAs Upregulated mRNAs 
miR-101 GSK3B, SOCS2 
miR-1246 GSK3B 
miR-146a ABL2, IRAK1 
miR-148b ABL2, CDC25B, PDK1 
miR-181a ABL2, MAP2K1, MAP3K3, MAP4K4, MKNK2 
miR-193a-3p MAP3K3 
miR-200a ABL2, CBL, CDC25B, MAP3K3, MAP4K4, PRKAR1A 
miR-200b CBL, CRKL, MAP4K4, PLCG1, PRKAR1A, PTPN11 
miR-21 MEF2C 
miR-223 MEF2C 
miR-26b ABL2, GSK3B, MEF2C, MKNK2 
miR-320e CRKL, MAP3K3 
miR-3609 CRK, GSK3B, MEF2C, MKNK2 
miR-3647-3p ABL2, CBL, CRK, CXCR5, MEF2C, PTPN11 
miR-4267 GSK3B, MAP3K3, MEF2C, PPP1CA 
miR-4324 CDC25B, MAP3K3, MKNK2, PRKACA 
miR-454 CDKN1A, MAP4K4, PDK1 
miR-659 GSK3B, MEF2C, SOCS2 
Upregulated 
miRNAs Downregulated mRNAs 
miR-1915 PIK3R3 
miR-301a PRKACB, SPHK2 
miR-3190 RPS6KB1 
miR-548h CCNB1,CCNG2,IL7,RPS6KA6 
miR-548m CCNG1 
miR-762 CALM3 
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  2.5.6 PGE2-ZEB1-miR-200b-PLCG1 may represent one 
axis underlying the role of PGE2 in prostate cancer development and 
progression 
 
miR-200b and the PLCG1 gene was among the miRNA:mRNA anticorrelated 
pairs we determined. This miRNA:mRNA binding had been validated in breast 
cancer cell lines by Dr. O Sahin's group and found to regulate cell proliferation 
and invasion (38); however, no study has been performed in prostate cancer 
cells focusing on this regulatory module. To assess their expression levels, we 
applied qRT-PCR to miR-200b and PLCG1 gene transcript. miR-200 a and b 
exhibited a 4-fold and 3-fold decrease, respectively, in PC-3/PGE2 cells, while 
PLCG1 possessed about 3-fold increase (Figure 2.5). Notably, the protein 
product of PLCG1 showed a consistent increase with its gene transcript but with 
a relatively lower FC of about 1.75-fold (Figure 2.6).   
 
Similar to protein-coding genes, miRNAs are transcribed from the genome by 
RNA polymerase II and are subject to modulation under transcription factors. 
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One highlighted transcription factor which regulates the miR-200 family is ZEB1. 
ZEB1 and the miR-200 family are reciprocally linked in a feedback loop, which 
serves as a switch and activator of epithelial-to-mesenchymal transition (EMT) in 
development as well as in disease (39-41). Our qRT-PCR determined the mRNA 
level of ZEB1 increased in PC-3/PGE2 cells, which in turn, may lead to decrease 
of the miR-200 family (Figure 2.5); however, the increase of ZEB1 was not 
statistically significant after applying a t-test. This may be caused by the variation 
within biological triplicate, thus the experiments need to be repeated. 
Furthermore, PGE2 treatment increased the expression of ZEB1 in non-small 
lung cancer cells (39); thus the reason for increased ZEB1 in prostate cancer 
may be PGE2 over-production.  
 
Collectively, we identified a decrease of miR-200b and an increase of ZEB1 and 
PLCG1 in the PC3/PGE2 system. One predicted regulatory axis was that PGE2 
induced the expression of transcriptional repressor ZEB1. Increased ZEB1 
formed a negative regulatory loop with miR-200b and decreased expression of 
miR-200b. Decreased miR-200b augmented the expression of PLCG1. 
Increased PLCG1 may contribute to downstream signaling cascades, including 
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PI3K and MAPK (Figure 2.5) (42-44), leading to acceleration of cell growth, 
proliferation, survival, and invasion. We did observe that PC-3/PGE2 cells had a 
higher proliferation rate compared to control PC-3 cells by MTT proliferation 
assay (Figure 2.7).  
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Figure 2.5: qRT-PCR validation of DE miRNAs and mRNAs implied in the 
proposed PGE2-ZEB1-miR-200b-PLCG1 axis 
miRNA and mRNA expression in PC-3/PGE2 cells and in control PC-3 cells were 
quantified by qRT-PCR. U6 and RNU48 were applied as endogenous house-keeping 
genes for assayed miRNAs, while GAPDH and β-actin were applied for assayed mRNAs. 
The height of columns indicated FCs of particular miRNA or mRNA expression between 
PC3/PGE2 cells and control PC-3 cells (FCs were set to one). Error bars depicted SEM of 
three biological replicates. Significance of differences between PC-3 cells (control) and 
PC-3/PGE2 cells was calculated by 2-tailed Student's t-test and are represented by p-
value. *** represented a p-value < 0.001, ** represented a p-value < 0.01, * represented 
a p-value < 0.05, and no asterisk represented no significant differences (p-value > 0.05).  
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Figure 2.6: Western blots validation of PLCG1 expression in control PC-3 cells (lane 
1) and PC-3/PGE2 cells (lane 2).   
Protein expression of PLCG1 in PC-3 cells with excessive endogenous PGE2 (PC-
3/PGE2) and in control PC-3 cells were examined by western blots. GAPDH was applied 
to indicate equal protein amount loaded in different lanes. Experiments were repeated 3 
times.  Quantification of protein levels of PLCG1 were calculated based on densitometry. 
Amount of PLCG1 proteins was normalized to GAPDH. Results were represented as 
mean ± SEM. Significance of differences between PC-3 cells (control) and PC-3/PGE2 
cells was calculated by two-tailed Student's t-test and are represented by p-value. ** 
represented a p-value < 0.01.  
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Figure 2.7: MTT proliferation assay on PC-3/PGE2 cells and control PC-3 cells 
Equal number of cells was seeded into 6-well culture plates on the first day. Cells were 
assayed with the MTT proliferation kit (ATCC) on the subsequent day 1 to day 6, 
continuously. Absorbance of colorimetric signal from each well was measured at 570 nm 
using a microtiter plate reader. The proliferation rate of PC-3/PGE2 cells was compared 
with that of control cells after subtracting the intensity from no-cell blank control wells. 
Relative proliferation was represented by average absorbance and standard error of mean 
from three biological replicates.  
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2.6 Discussion 
 
PGs are implicated in various types of cancers and their upstream PGES and 
COX enzymes are primary targets of multiple NSAIDs (nonsteroidal anti-
inflammatory drugs) such as aspirin, ibuprofen, and indomethacin (17, 18). 
Among the PG family, PGE2, the most abundant PGs in prostate cancer, was 
first identified in human colon adenomas (21, 45). PGE2 and its two inducible 
synthases, COX-2 and mPGES-1 are increased in response to inflammation and 
cancer. Impaired COX-2/mPGES-1/PGE2/EP1-4 pathway in various cancers 
(such as breast, prostate, stomach, and pancreas cancer) can give rise to cell 
proliferation, invasion, adhesion, metastasis, and angiogenesis (22, 46-49). 
Previously, intensive studies have been carried out to investigate the PGE2 
downstream molecular basis which is involved in signaling pathways and to 
determine the mechanism underlying its effect as a pro-inflammatory factor (17, 
22).  
 
Wang et al., 2007 elucidated that, in prostate cancer, PGE2 upregulated the 
production and secretion of VEGF through EP2 and EP4 receptors in a cAMP 
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dependent manner (50). Also, increased PGE2 augmented the activation of 
Erk1/2 and Akt; thus enhanced MAPK and PI3K/Akt signaling pathways. A 
similar conclusion was achieved by Jain et al., 2008, showing that PGE2 induced 
the activation of EGFR/MAPK signaling cascade and the expression of VEGF, 
which collectively influenced cell motility and angiogenesis in prostate cancer 
(22).  
 
Another notable axis through which PGE2 exerts its effects is by transactivating 
EGFR/ Met receptor tyrosine kinases and ultimately triggering cell growth, 
invasion and migration in diverse cancer types, including hepatocellular 
carcinoma, colon cancer, and prostate cancer (49, 51-53). Studies applied to 
other cancer types demonstrated downstream modules of PGE2 included 
Raf/MEK/Erk, which led to increased cell proliferation; PLC/PKC/c-Src/NF-κB, 
which mediated cell migration; and PI3K/Akt, which controlled cell invasion and 
angiogenesis (25, 54, 55).  
 
Despite the knowledge we accumulated on PGE2 in stimulating inflammation and 
cancer, there is no systematic profiling available regarding potential alternations 
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in the expression of miRNAs and gene mRNAs upon PGE2 stimulation in 
prostate cancer. In this study, we concomitantly profiled miRNAs and gene 
mRNAs in both PC-3/PGE2 cell and control PC-3 cells. The fusion recombinant 
enzyme expressed by COX-2-10aa-mPGES-1 plasmid mimic the biofunction of 
inducible COX-2 and mPGES-1 synthases which efficiently metabolize AA to 
produce endogenous PGE2. Once PGE2 is stimulated in prostate cancer, we 
identified both significant down and upregulation of miRNA expression by miRNA 
microarray and validated a portion of them by qRT-PCR. 
 
Remarkably, among the downregulated miRNAs, four of them (miR-101, miR-
146a, miR-200a, and miR-200b) have been previously proved to function as 
tumor suppressors in prostate cancer (56-58). In addition to the report of aberrant 
miRNA found in prostate cancer, some of decreased miRNAs in response to 
PGE2 are associated with other types of cancers. For instance, miR-148b is 
determined to suppress cancer growth and is frequently downregulated in gastric 
cancer and colorectal cancer (59, 60). Furthermore, miR-375 is playing a pivotal 
role as a tumor suppressor in diverse types of cancer, such as gastric cancer, 
head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma 
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(HCC), and esophageal squamous cell carcinoma (ESCC) (61-65). Notably, 
upregulated miRNAs after PGE2 induction are poorly characterized and await 
further investigation.  
 
Meanwhile, since current miRNA target prediction algorisms usually provide false 
positive outcomes, we combined the putative miRNA:mRNA regulatory pairs 
from in silico miRNA target prediction approach with anticorrelated miRNA:mRNA 
expression profiles. Therefore, we narrowed the possible altered miRNA:mRNA 
pairs in response to PGE2 stimulation.  
  
Based on the comprehensive profile examination and miRNA:mRNA pairwise 
screening, we predicted one possible axis that may lead to overexpression of 
PLCG1 in PC-3/PGE2 cells. PLCG1 is critical in cancer growth, survival, invasion, 
and migration. It is activated by extracellular stimuli including growth factors, 
hormones, and neurotransmitters. Once activated, PLCG1 further catalyzes PIP2 
into IP3 and DAG, whereas PLCG1 also cross talks with PI3K and MAPK 
signaling pathways (42-44).  
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At the post-transcriptional level, miR-200b potentially targeted and negatively 
regulated PLCG1 expression in PC-3/PGE2 cells (38). The low expression of the 
miR-200 family in these cells may be due to PGE2 triggered high expression of 
ZEB1, which acts as a transcriptional repressor to miR-200 family (39-41).  
 
We proposed a model to show the potential regulatory mechanism of PGE2 in 
PC-3 cells. Besides the known signaling cascades, we predicted PGE2 may also 
exert its function through PGE2-ZEB1-miR-200-PLCG1 axis (Figure 2.8).  
 
Some limitations are associated with our study. One limitation is that we did not 
individually examine the miRNAs and/or mRNAs which may be altered by COX-2 
or mPGES-1. In our study, we applied a hybrid vector which can express a fusion 
protein in PC-3 cell line. This fusion protein combined COX-2 and mPGES-1 with 
a 10-aa linker so that it can efficiently convert endogenous AA into PGE2. We 
assumed that DE miRNAs/mRNAs we detected were due to upregulation of 
PGE2; however, this raises the possibility that differential expression may be 
caused by overexpression of COX-2 or mPGES-1. Moreover, miRNAs regulate 
mRNA transcripts of target genes at post-transcriptional level, which our 
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approach would not identify. Besides that, DNA methylation, transcription-factor 
regulation, and other forms of post-transcriptional modification are also involved 
in the modulation of mRNA transcripts. Thus, we present this as a preliminary 
study for the regulation of gene expression through miRNAs. Meanwhile, 
validation of interaction between DE miRNAs and their putative target mRNAs 
requires more intensive work.  
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Figure 2.8: Proposed pathway underlying the mechanism of PGE2 function in 
prostate cancer (PC-3 cells)  
PGE2 transactivates receptors including EGFR, Met, and VEGFR, which further trigger 
downstream signaling cascades including PI3K pathway, MAPK pathway and PKC-
dependent calcium signaling pathway. One novel axis we proposed along with the 
existing paths is that PGE2 may induce expression of a transcriptional repressor ZEB1. 
ZEB1 may suppress the expression of miR-200b. Decreased level of miR-200b may lead 
to enhanced expression of its putative target gene, PLCG1. PLCG1 converts PIP2 into 
IP3 and DAG, finally resulting in the release of endogenous calcium level and the 
activation of subsequent calcium signaling pathway. Molecules downstream of PLCG1 
also cross-talk with MAPK and PI3K pathways. Overall, the implied pathways are 
suggested to lead to cell growth, proliferation, migration, and survival. 
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2.7 Conclusion 
 
In conclusion, we identified a subset of miRNA:mRNA pairs whose expression 
had been disturbed due to PGE2 upregulation in prostate cancer cells (PC-3 
cells). Our findings suggested that miRNAs may play a role in negatively 
regulating putative target mRNA expression and thus contribute to PGE2-
induced disturbances of key signaling cascades.  The PGE2-ZEB1-miR-200b-
PLCG1 axis, together with other unraveled PGE2-induced miRNA:mRNA pairs, 
may suggest a possible novel regulatory mechanism of PGs in prostate cancer. 
This work provide potential therapeutic candidates for the development of 
miRNA-based gene therapy against PGE2-associated diseases.   
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_ 
Chapter 3: MicroRNA Expression Profiling and Pathway 
Analysis of Porcine Adipose Tissues Revealed a Novel 
Potential Molecular Link Between Accumulated Body 
Mass, Inflammation, and Cancer 
_ 
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3.1 Key words 
 
porcine adipose-enriched microRNA, metabolism, inflammation, cancer, 
miRFocus pathway enrichment analysis 
 
3.2 Abstract 
 
Impaired expression of miRNA is implied in various types of cancers as well as 
metabolic disorders, such as type II diabetes and obesity. Epidemiologic studies 
have revealed a strong association between body mass index (BMI) and the 
development of inflammatory disorders and/or cancers, yet the molecular basis 
of such a correlation and whether miRNAs are involved is little known. We thus 
set to identify novel signatures and critical predicted pathways in adipose tissues 
by exploring their miRNA profiles using the pigs as a model animal. Strikingly, a 
significant portion of identified adipose-enriched miRNAs was previously reported 
to be involved in metabolism, inflammatory responses, and oncogenesis. 
Pathway enrichment analysis provided further evidence that adipose-enriched 
miRNAs shared major pathways with breast cancer overexpressed miRNAs. 
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These findings suggested that adipose-enriched miRNAs may contribute to 
obesity-associated increase of cancer risk. Thus they are of high potential to 
serve as diagnostic and therapeutic targets for the above-mentioned diseases.   
 
3.3 Introduction 
 
Obesity, which is excess accumulation of adipose tissues, has dramatically 
increased in the past decades. Obesity has been previously demonstrated to 
exhibit a significant impact on the increased risk of insulin resistance, diabetes, 
and cardiovascular diseases (66). Recent research further elucidated that obesity 
is associated with the increased frequency of many common cancers, including 
breast cancer, prostate cancer, colon cancer, and pancreatic cancer (67). 
Moreover, most recent research determined that obesity may contribute to the 
rise in incidence of rheumatoid arthritis, which is a chronic and systematic 
inflammatory disorder that affects primarily the joints as well as surrounding 
tissues and organs (68, 69).  
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Obesity exerts its effect on inflammation and cancer mainly through adipocytes in 
adipose tissues that secrete a variety of cytokines, chemokines, growth factors, 
and hormones. The state of obesity accumulates more adipocytes and increases 
the release of inflammatory cytokines, such as TNF-α, IL-6, and PAI1 (67). 
Therefore, obesity itself has been recognized as a chronic, low-grade 
inflammatory state.  
 
Although, epidemiologic studies have provided a positive correlation between 
obesity and the development of inflammatory diseases and/or cancers, the 
molecular-based mechanism underlying this correlation, especially on the miRNA 
level, is little known and awaits thorough study. In this study, we conducted 
miRNA profiling in a large number of tissue-specific samples obtained from six 
adipose depots (i.e., upper and inner layers of back fat, greater omentum, 
mesenteric adipose, retroperitoneal adipose, and abdominal subcutaneous 
adipose, respectively) together with two phenotypically distinct skeletal muscle 
tissues (i.e., longissimus dorsi muscle and psoas major muscle). Pigs were 
selected as the model animal for their easy-to-access feature and close 
phylogenetic distance to humans (70). Pigs share a similar genome size with 
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humans; however, their identified number of miRNAs is only ~13% (there are 255 
unique mature miRNAs in pigs) to that of humans in miRBase v18 (released in 
November 2011). Therefore porcine miRNAome requires systemic profiling (27).  
 
Initially, we used small RNA sequences that we identified from pigs in our 
previous study as candidates for microarray probe design. The probe sequences 
covered reported porcine miRNAs, potential novel porcine miRNAs, and their 
isoforms.   Based on the array, we performed a systematic screening of porcine 
adipose and muscle tissues (71). Then from the miRNA profiles, we determined 
a set of miRNAs which were specifically of high-abundance in adipose tissues 
compared to in muscle tissues (adipose-enriched miRNAs) and further 
demonstrated their sequence and expression conservation in humans.  
 
Moreover, we explored predictions related to biological function on this set of 
adipose-enriched miRNAs. We identified a majority of adipose-enriched miRNAs 
that were reported to be inflammation induced or oncogenic by published studies. 
Their distribution within six types of adipose tissues further differed between 
subcutaneous adipose tissues (SAT) (i.e., upper layer of back fat, inner layer of 
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back fat, and abdominal subcutaneous adipose) and visceral adipose tissues 
(VAT) (i.e., greater omentum, mesenteric adipose, retroperitoneal adipose), 
which suggested expression of miRNAs was highly tissue-specific.  
 
Finally, to evaluate the global impact of adipose-enriched miRNAs and to explain 
the correlation between body mass index (BMI) and the risk of cancer at the 
scale of signaling cascades, we characterized enriched KEGG pathways of both 
adipose-enriched miRNAs and breast cancer overexpressed miRNAs (35-37). 
These findings suggested a proposed link of miRNAs that associated obesity 
with increased risk of cancers, and will potentially contribute to miRNA-based 
biomarker discovery and therapeutic intervention.  
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3.4 Materials and methods  
 
  3.4.1 Adipose and muscle tissues 
 
Three female Landrace pigs (a white, Western breed) at 210-days-old were used 
to harvest the adipose and muscle tissues. Six adipose tissues from different 
body sites (i.e., upper and inner layers of backfat, greater omentum, mesenteric 
adipose, retroperitoneal adipose, and abdominal subcutaneous adipose, 
respectively) together with two phenotypically distinct skeletal muscle tissues (i.e., 
longissimus dorsi muscle and psoas major muscle) were subject to array 
screening.  
 
  3.4.2 Cell culture of human adipocytes  
 
Cryopreserved human preadipocytes derived from subcutaneous and visceral 
depots of both lean (BMI<25.0 Kg/m2) and obese (BMI>30.0 Kg/m2) female 
donors. SP-F-1 were obtained from subcutaneous adipose of lean female donor 
and SP-F-3 were obtained from subcutaneous adipose of obese female donor. 
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OP-F-1 were obtained from visceral adipose of lean female donor and OP-F-3 
were obtained from visceral adipose of obese female donor (Zen-Bio, Inc.). All 
four kinds of human adipocytes were employed for the conservation analysis of 
porcine miRNAs. Preadipocytes were plated into 6-well plates and cultured in 
preadipocyte medium (OM-PM; Zen-Bio, Inc.) at 37ºC with 5% CO2. After plating 
cells for 24 hours, they became confluent and thus were ready for differentiation 
induction using differentiation medium (DM; Zen-Bio, Inc.) which contained 
isobutylmethylxanthine (0.20 mM) and PPARγ agonist (10 µM). Seven days after 
differentiation, the medium was again switched to adipocyte medium (AM; Zen-
Bio, Inc.) specially composed of biotin (33 µM), pantothenate (17 µM), human 
insulin (100 nM), and dexamethasone (1 µM). Fourteen days after differentiation, 
cells assumed a round shape with large oil droplets in the cytoplasm and were 
considered as mature adipocytes, hence were suitable for RNA extraction. All 
four adipocyte primary cell cultures were performed in biological triplicate.  
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  3.4.3 Cell culture of human cell lines  
 
Human cell lines were obtained from the American Type Culture Collection 
(Rockville,  MD). The non-tumorigenic human mammary epithelial cell line, 
MCF-10A, was maintained in 1:1 mixture of DMEM and Ham's F-12 medium 
(Invitrogen, 11885 and 11765) supplemented with 5% fetal bovine serum (FBS, 
Sigma, F2442), 10 µg/ml insulin, 20 ng/ml epidermal growth factor, and 0.5 ng/ml 
hydrocortisone (Sigma). Breast cancer T47D cells were cultured in DMEM/Ham's 
F-12 medium (1:1) with 5% FBS and MCF-7 cells were cultured in DMEM 
medium with 5% FBS. All applied culture medium contained 1% 
penicillin/streptomycin.  
 
  3.4.4 Total RNA extraction  
 
Total RNA from porcine tissue samples and human adipose primary cell cultures 
were extracted and purified with mirVanaTM miRNA isolation kit (Ambion) 
according to the manufacturer’s specifications. RNA concentration was estimated 
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by NanoDrop ND-1000 spectrophotometer (Nano Drop) and RNA integrity was 
evaluated by Agilent 2100 Bioanalyzer (Agilent Technologies).  
 
  3.4.5 miRNA microarray design 
 
Innovative probe design pipeline started with existing sequenced sequences 
(sequ-seqs) generated by Illumina high-throughput small RNA sequencing 
technology as probe candidates. In particular, 10 small RNA sequ-seq libraries 
obtained by Li et al. (2010), which represented the full porcine lifespan and were 
derived from 60 tissues of both sexual traits, were employed for initial probe 
design (71). Mammalian miRNAs collected from miRBase v15 were determined 
as templates (reference miRNA sequences). Considering the heterogeneous 
distribution of sequ-seqs to templates, probes were designed to cover 13 
mammalian species (Figure 3.1). A subset of sequ-seqs, which did not map to 
known mammalian miRNAs, was also grouped into the probe pool for discovery 
profiling (they are referred to as PCC probes). Final probe content consisted of 
1,572 unique experimental sequences representing a comprehensive repertoire 
of mammalian known miRNAs, potential novel miRNAs and their statistically 
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significant isoforms derived from sequ-seqs. Microarray layout was designed to 
contain three technical replicates for each experimental sequence. It also 
incorporated control probes to closely monitor microarray synthesis and sample 
processing quality (72, 73).   
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Figure 3.1: Species coverage and distribution of miRNA microarray probes 
Probes were designed to cover 13 mammalian species. The largest portion of probes was 
intended to profile porcine miRNAs. PCC represented probes for potential novel 
miRNAs from sequencing reads (our candidate sequences for array probe design) which 
can not be mapped to mature miRNA sequences of any mammalian species. The data 
labels indicated "species, number of probes, and percentage to total probes". 
Abbreviations for species: Sus scrofa, ssc; Homo sapiens, hsa; Bos taurus, bta; 
Monodelphis domestica, mdo; Canis familiaris, cfa; Ornithorhynchus anatinus, oan; Mus 
musculus, mmu; Rattus norvegicus, rno; Pan troglodytes, ptr; Pongo pygmaeus, ppy; 
Macaca mulatta, mml; Lagothrix lagotricha, lla; and Ateles geoffroyi, age.  
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  3.4.6 miRNA microarray profiling 
 
About 0.5 µg of total RNA was 3’ dephosphorylated by Antarctic phosphatase 
(New England Biolabs, Catalog No. M0289S) and purified by RNeasy MiniElute 
Cleanup Kit (Qiagen, Catalog No. 74204). Specific oligonucleotide adaptors were 
ligated to the 3’ of RNA and followed by fluorescent dendrimer-dye conjugation. 
Tagged RNA samples were hybridized on a μParaflo microfluidic chip at 40 °C 
for 16 hours using a micro-circulation hybridization station (LC Sciences). 
Subsequently, Alexa Fluor® 3 dyes (Invitrogen) were circulated to samples for 
staining at 34 °C for 2 hours. Array images were acquired on a GenePix 4400B 
laser scanner (Molecular Device) in 532 nm channel. Images were first digitalized 
with Array-Pro Analyzer (MediaCybernetics) to quantify signal mean and 
standard deviation of each probe spot on the array surface. Profilings were 
performed using three biological replicates from three individual pigs.  
 
 
 
  
- 89 -
 
  3.4.7 miRNA microarray data analysis 
 
Microarray data were further processed by background subtraction and LOWESS 
(locally weighted regression) normalization so that biological variations between 
samples could be identified. Significance of differences between porcine adipose 
and muscle miRNA profiles was analyzed by Student t-test with p < 0.01, 0.05, or 
0.1 respectively (72). Heatmap and clustering of differentially expressed (DE) 
miRNAs were generated by MeV software (The Institute for Genome Research).  
 
  3.4.8 miRNA Illumina sequencing 
 
Six different adipose tissues and two skeletal muscle tissues from three female 
Landrace pigs were employed for small RNA sequencing. For each sequencing 
sample, equal quantities (5 µg) of small RNA isolated from three female 
Landrace pigs were pooled. Approximately 15 µg of small RNA representing 
each tissue was used for subsequent library preparation and sequencing 
according to Illumina's manufacturer protocols. The reads were first passed 
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through the filters of Illumina’s Genome Analyzer Pipeline software and then 
were subject to the in-house developed ACGT101 program, where reads were 
counted, grouped into sequence families, and mapped to available mammalian 
miRNAs in miRBase v15 (71, 73).  
 
  3.4.9 qRT-PCR 
 
Ten adipose-enriched miRNAs derived from porcine adipose tissues were 
validated in human adipocyte primary cell cultures by qRT-PCR using NCodeTM 
EXPRESS SYBR® GreenERTM miRNA kit (Invitrogen) on an ABI 7900HT 
instrument (Applied Biosystems) according to manufacturers’ protocols. 
Sequences of miRNA specific forward primers and RNU48 endogenous control 
primer were provided in Table 3.1. The ∆∆Ct method was applied to calculate FC 
of surveyed adipose abundant miRNAs. Corresponding miRNA expression in 
human muscles was considered as reference. The relative FCs for each miRNA 
were plotted and error bar indicated SEM from three biological replicates. 
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Table 3.1: PCR primers used in the qRT-PCR validation assays 
 
miRNA Primer 
ssc-miR-103 CAGCATTGTACAGGGCTATGA 
ssc-miR-107 CAGCATTGTACAGGGCTATCA 
ssc-miR-130a CAGTGCAATGTTAAAAGGGCAT 
ssc-miR-143 GGTGAGATGAAGCACTGTAGCTC 
ssc-miR-148a GCTCAGTGCACTACAGAACTTTGT 
ssc-miR-193a-5p GCGGGCGAGATGAAAAA 
ssc-miR-199a-5p CCCAGTGTTCAGACTACCTGTTC 
hsa-miR-200b GGTAATACTGCCTGGTAATGATGA 
hsa-miR-221 AGCTACATTGTCTGCTGGGTTTC 
RNU48 AGTGATGATGACCCCAGGTAACTC 
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  3.4.10 miRNA pathway enrichment analysis  
 
Enriched biological pathways associated with a set of miRNAs were investigated 
with miRFocus (http://www.mirfocus.org/), an open resource web-tool. First, 
putative miRNA target genes were retrieved and merged from 5 target prediction 
algorithms: MiRanda (http://www.microrna.org), MirTarget2 (miRDB: 
http://mirdb.org), PicTar (http://pictar.mdc-berlin.de), TargetScan 
(http://www.targetscan.org) and DIANA microT 
(http://diana.cslab.ece.ntua.gr/microT) (33, 74-80); together with 4 validated miR-
target gene databases: MiRecord (http://mirecords.biolead.org), miR2Disease 
(http://www.mir2disease.org), TarBase (http://diana.cslab.ece.ntua.gr/tarbase) 
and miRTarbase (http://mirtarbase.mbc.nctu.edu.tw) (81-84). To enhance the 
accuracy and reliability of target prediction, common target genes shared by at 
least 3 algorithms were selected into target pool. Then, the target pool of input 
miRNAs was mapped to KEGG database in order to identify enriched biological 
pathways (35-37). The significance of each pathway was assessed by Fisher's 
exact test and represented by p-value.  
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3.5 Results and discussion  
 
  3.5.1 Identification and validation of adipose-enriched 
miRNAs 
 
To systematically identify miRNAs which were universally enriched in porcine 
adipose tissues, we profiled miRNA expression of adipose tissues from six 
different fat depots (upper and inner layers of back fat, greater omentum, 
mesenteric adipose, retroperitoneal adipose, and abdominal subcutaneous 
adipose) together with muscle tissues from two muscle depots (longissimus dorsi 
muscle and psoas major muscle) using a high-definition miRNA microarray 
approach.  
 
As shown in Table 3.4, out of 1,572 unique probes, 56 miRNAs exhibited distinct 
expression patterns between the two types of tissues after student t-test with p-
value < 0.05 (Table 3.2 and Table 3.3). Among them, 32 miRNAs (including miR-
103a, miR-107, miR-122, miR-146, and miR-21) were highly expressed in 
adipose tissues; while in contrast, 24 miRNAs (including miR-1, miR-128, miR-
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133, miR-181, and miR-193) were highly expressed in muscle tissues (Table 3.4 
and Figure 3.2).  
 
We further compared out miRNA microarray results to that of Illumina small RNA 
sequencing (NGS) using the exactly same set of porcine tissue samples. Copy 
number of sequenced-sequences (sequ-seqs) satisfying quality criterias were 
compared to the probe intensity from microarray of the same miRNA. In Figure 
3.3, we evaluated reproducibility and correlation between the two platforms by 
computing the FC ratios of miRNA expression between the two types of tissues. 
We determined that Person correlation coefficient (r) between NGS and 
microarray on the 56 miRNAs determined as DE by microarray was 0.88, 
supporting the reproducibility and reliability of our miRNA microarray data.  
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Table 3.2: miRNAs highly expressed in porcine adipose tissues 
Index miRNA ID 
Expression 
in adipose 
tissues 
Expression 
in muscle 
tissues 
Log2(FC) p-value Significance label 
1 hsa-let-7b 3,261 1,603 1.02 1.10E-02 ** 
2 ssc-let-7c 6,544 3,512 0.90 2.30E-03 *** 
3 ssc-let-7i 3,694 2,189 0.75 2.50E-02 ** 
4 bta-miR-21 12,967 7,305 0.83 2.03E-02 ** 
5 ssc-miR-100 7,080 4,393 0.69 3.78E-04 *** 
6 ssc-miR-103 3,263 1,049 1.64 8.73E-03 *** 
7 ssc-miR-107 3,483 981 1.83 4.06E-06 *** 
8 ssc-miR-122 83 3 5.03 2.82E-02 ** 
9 ssc-miR-130a 1,735 532 1.71 1.35E-06 *** 
10 ssc-miR-140* 1,017 309 1.72 6.92E-04 *** 
11 ssc-miR-143 6,965 2,755 1.34 2.87E-03 *** 
12 ssc-miR-145 19,044 8,491 1.17 1.28E-03 *** 
13 mmu-miR-145* 434 89 2.29 5.74E-04 *** 
14 hsa-miR-146a 2,753 484 2.51 9.85E-03 *** 
15 ssc-miR-146b 230 55 2.06 1.10E-02 ** 
16 ssc-miR-148a 9,529 2,453 1.96 6.05E-04 *** 
17 ssc-miR-152 2,827 977 1.53 1.94E-03 *** 
18 mmu-miR-155 838 78 3.43 1.57E-06 *** 
19 ssc-miR-185 330 122 1.44 2.64E-02 ** 
20 ssc-miR-193a-3p 812 249 1.70 2.40E-02 ** 
21 ssc-miR-193a-5p 1,177 265 2.15 1.86E-04 *** 
22 ssc-miR-199a-3p 8,795 2,721 1.69 1.79E-02 ** 
23 ssc-miR-199a-5p 7,613 2,663 1.52 4.82E-05 *** 
24 hsa-miR-199b-5p 2,566 1,127 1.19 5.48E-03 *** 
25 ssc-miR-199b* 10,467 2,860 1.87 1.33E-02 ** 
26 hsa-miR-200a 1,150 8 7.23 6.17E-03 *** 
27 hsa-miR-200b 897 5 7.35 2.75E-03 *** 
28 hsa-miR-203 611 94 2.71 1.95E-07 *** 
29 hsa-miR-221 1,023 145 2.82 9.25E-06 *** 
30 hsa-miR-320b 1,964 808 1.28 3.23E-04 *** 
31 hsa-miR-320d 1,018 508 1.00 4.85E-03 *** 
32 hsa-miR-375 916 3 8.33 3.30E-02 ** 
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Table 3.3: miRNAs highly expressed in porcine muscle tissues 
 
Index miRNA ID 
Expression 
in adipose 
tissues 
Expression 
in muscle 
tissues 
Log2(FC) p-value Significance label 
1 hsa-let-7d* 179 431 -1.26 1.10E-03 *** 
2 oan-let-7e 250 2,693 -3.43 5.84E-03 *** 
3 ssc-miR-1 32 79,491 -11.29 1.24E-14 *** 
4 ssc-miR-15a 2,797 7,544 -1.43 1.11E-09 *** 
5 ssc-miR-19b 2,057 3,526 -0.78 8.03E-04 *** 
6 cfa-miR-20b 321 515 -0.68 4.40E-03 *** 
7 hsa-miR-26b 4,560 8,845 -0.96 1.46E-03 *** 
8 hsa-miR-28-5p 661 3,273 -2.31 2.13E-06 *** 
9 ssc-miR-101 1,858 5,670 -1.61 3.73E-08 *** 
10 ssc-miR-106a 760 1,175 -0.63 6.61E-03 *** 
11 ssc-miR-128 326 8,706 -4.74 5.47E-10 *** 
12 ssc-miR-133a 131 52,089 -8.63 1.27E-14 *** 
13 ssc-miR-133b 250 59,388 -7.89 1.80E-14 *** 
14 ssc-miR-151-3p 303 940 -1.63 2.39E-03 *** 
15 ssc-miR-151-5p 2,880 8,333 -1.53 1.96E-03 *** 
16 ssc-miR-181a 2,153 3,303 -0.62 4.41E-02 ** 
17 bta-miR-193b 1,556 6,374 -2.03 2.24E-05 *** 
18 ssc-miR-196a 99 176 -0.83 5.02E-04 *** 
19 ssc-miR-196b 138 144 -0.07 1.40E-02 ** 
20 ssc-miR-206 17 18,417 -10.09 1.62E-10 *** 
21 hsa-miR-362-3p 163 400 -1.30 3.77E-03 *** 
22 hsa-miR-362-5p 156 301 -0.95 4.54E-02 ** 
23 hsa-miR-376c 129 403 -1.64 1.39E-05 *** 
24 hsa-miR-487b 128 453 -1.83 1.39E-03 *** 
 
Note: Log2(FC) calculated as log2(miRNA expression in adipose/expression in muscle) 
Significance label: *** p-value<0.001, ** p-value<0.01 
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Table 3.4: DE miRNAs between porcine adipose and muscle tissues 
Adipose-enriched miRNAs Muscle-enriched miRNAs 
miRNA ID Log2Ratio# p-value miRNA ID Log2Ratio# p-value 
hsa-let-7b 1.02 ** hsa-let-7d* -1.26 ***
ssc-let-7c 0.90 *** oan-let-7e -3.43 ***
ssc-let-7i 0.75 ** ssc-miR-1 -11.29 ***
bta-miR-21 0.83 ** ssc-miR-15a -1.43 ***
ssc-miR-100 0.69 *** ssc-miR-19b -0.78 ***
ssc-miR-103 1.64 *** cfa-miR-20b -0.68 ***
ssc-miR-107 1.83 *** hsa-miR-26b -0.96 ***
ssc-miR-122 5.03 ** hsa-miR-28-5p -2.31 ***
ssc-miR-130a 1.71 *** ssc-miR-101 -1.61 ***
ssc-miR-140* 1.72 *** ssc-miR-106a -0.63 ***
ssc-miR-143 1.34 *** ssc-miR-128 -4.74 ***
ssc-miR-145 1.17 *** ssc-miR-133a -8.63 ***
mmu-miR-145* 2.29 *** ssc-miR-133b -7.89 ***
hsa-miR-146a 2.51 *** ssc-miR-151-3p -1.63 ***
ssc-miR-146b 2.06 ** ssc-miR-151-5p -1.53 ***
ssc-miR-148a 1.96 *** ssc-miR-181a -0.62 **
ssc-miR-152 1.53 *** bta-miR-193b -2.03 ***
mmu-miR-155 3.43 *** ssc-miR-196a -0.83 ***
ssc-miR-185 1.44 ** ssc-miR-196b -0.07 **
ssc-miR-193a-3p 1.70 ** ssc-miR-206 -10.09 ***
ssc-miR-193a-5p 2.15 *** hsa-miR-362-3p -1.30 ***
ssc-miR-199a-3p 1.69 ** hsa-miR-362-5p -0.95 **
ssc-miR-199a-5p 1.52 *** hsa-miR-376c -1.64 ***
hsa-miR-199b-5p 1.19 *** hsa-miR-487b -1.83 ***
ssc-miR-199b* 1.87 **       
hsa-miR-200a 7.23 ***     
hsa-miR-200b 7.35 ***     
hsa-miR-203 2.71 ***     
hsa-miR-221 2.82 ***     
hsa-miR-320b 1.28 ***     
hsa-miR-320d 1.00 ***     
hsa-miR-375 8.33 **     
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Figure 3.2: Heatmap and hierarchical clustering of DE miRNA expression in 
adipose and muscle tissues 
z-scores (z = (x - μ) / σ, x = raw score or observation to be standardized, μ = mean of the 
population, and σ = standard deviation of the population) from 24 normalized miRNA 
microarray data sets were hierarchically clustered in gene dimension and plotted as a heat 
map. t-test was performed between 6 types of adipose samples (left) and 2 types muscle 
samples (right). Each type of samples contained three biological replicates. Probes with 
p-value <0.05 after t-test were presented in the plot. Dendrograms on the left side 
indicated the euclidean distance among miRNAs. Red and Green color denoted z-scores 
ranging from -2.0to 0 to +2.0. Red represented high expression levels  and green low 
expression. Detailed expression and ratio changes of miRNAs were shown in Table 3.2, 
Table 3.3, and Table 3.4.  
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Figure 3.3: Validation of DE miRNA obtained from microarray by Illumina small 
RNA sequencing 
miRNA expression FCs were computed either based on intensity as generated from 
microarray or based on miRNA copy number as determined from Illumina small RNA 
sequencing. The y-axis represented the log2 transformed FC between adipose tissues and 
muscle tissues of 12 DE miRNAs (shown in x-axis). Tested DE miRNAs exhibited 
consistent high expression in adipose tissues or in muscle tissues within the two 
platforms we used and thus we validated the microarray data we obtained.  
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  3.5.2 Porcine adipose-enriched miRNAs were conserved 
in human 
 
To date, 255 mature porcine miRNA sequences have been identified and 
deposited to miRBase v18 (released in November 2011) (27); however, rarely 
have any functional and pathway annotations been unraveled of biomedical 
interest (73, 85, 86). The poorly studied porcine miRNAome requires 
comparative studies between porcine and human miRNAs (87).  
 
In order to apply our accumulated knowledge of human miRNAs to the porcine 
adipose-enriched miRNAs we obtained, we first aligned and compared 
sequences of porcine adipose-enriched miRNAs, which were assessed from 
complimentary of their corresponding microarray probe sequences, with their 
human orthologs. Results in Table 3.5 provided us with evidence that sequences 
between porcine adipose-enriched miRNAs and their human orthologs were 
either identical or highly conserved, with only one to two-nucleotide differences at 
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5' and/or 3' end, which was not the critical position for miRNAs to exert their 
biological function.  
 
Moreover, expression of corresponding human orthologs to porcine adipose-
enriched miRNAs was determined by qRT-PCR approach. We examined four 
kinds of human adipocytes (as shown in different colors in Figure 3.4) sourced 
from either subcutaneous or omental depot of both lean (BMI<25.0 Kg/m2) and 
obese (BMI>30.0 Kg/m2) female donors. Relative expression of each miRNA in 
human adipocytes versus in human muscles was presented as FCs in y-axis. 
Based on the expression patterns of miRNAs, we concluded that porcine 
adipose-enriched miRNAs exhibited consistent high expression in human 
adipocytes but not in human muscles.  
 
Overall, we confirmed that both sequences and expression of miRNAs in pigs 
were conserved in humans, which were consistent with the close phylogenetic 
distance between pigs and humans and further suggested the pigs as a valuable 
animal model for biomedical research.  
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Figure 3.4: Quantification of the expression of porcine adipose-enriched miRNAs in 
human adipocytes by qRT-PCR approach 
Expression of 9 adipose-enriched miRNAs originally identified from pigs was examined 
in human adipocytes using qRT-PCR. RNU48 snRNA was used as endogenous control 
and its expression was uniform across all human samples. Expression of miRNA was first 
normalized to endogenous control. Then FCs of miRNA expression between adipocytes 
and muscles were calculated by the ∆∆Ct method. Columns of different colors 
represented 4 kinds of human adipocytes obtained from subcutaneous and omental depots 
of both lean (BMI<25.0 kg/m2) and obese (BMI>30.0 kg/m2) female donors. The height 
of columns indicated FCs of miRNA expression between human adipocytes and muscles. 
Data was expressed as mean ± SEM (n=3 biological replicates). Significance of 
differences was calculated by two-tailed Student's t-test and are represented by p-value. 
*** represented a p-value < 0.001, ** represented a p-value < 0.01, * represented a p-
value < 0.05, no asterisk represented no significant differences (p-value > 0.05).  
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  3.5.3 Adipose-enriched miRNAs were involved in 
metabolism  
 
Adipose tissues are the largest energy reservoir for triglycerides. Mature 
adipocytes, the major cell type of adipose tissues, uptake glycerol and fatty acid 
and synthesize them into triglyceride (lipogenesis). The store of triglycerides can 
be hydrolysed to release fatty acid into body circulation (lipolysis) (88). Insulin 
plays a crucial role in lipid metabolism by promoting glucose uptake which is 
followed by lipogenesis, and inhibiting lipolysis (89). Dysregulation of energy 
deposition in adipose tissue, for instance, obesity, will lead to insulin-related 
disorders, such as insulin resistance and type 2 diabetes (88).  
 
Due to the function of adipose tissues in lipid and glucose metabolism, we 
determined that a set of adipose-enriched miRNAs (5 out of 32) were involved in 
metabolic processes in different types of tissues and/or cells as reported by 
published studies. For example, miR-103/107 mediates insulin sensitivity and 
control glucose homeostasis in mouse liver(12); miR-122, which is the most 
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prevalent miRNA in liver and is conserved among multiple species, controls 
cholesterol accumulation in mouse liver (13); miR-143 regulates lipid metabolism 
in liver and its expression is induced by obesity. Upregulated miR-143 impairs 
glucose homeostasis (14); miR-375 mediates glucose regulation of insulin gene 
expression and β cell growth in pancreas (15).  
 
Notably, the distribution and expression of metabolism related adipose-enriched 
miRNAs varied among the six adipose depots (Table 3.6). Their expression was 
consistently higher in adipose tissues than in muscle tissues, among them, miR-
107 was further enriched in retroperitoneal adipose, miR-143 in mesenteric 
adipose, and miR-375 in abdominal subcutaneous adipose. 
 
To sum up, adipose tissue, as a type of active tissue for body metabolism, 
contains highly expressed miRNAs (adipose-enriched miRNAs) which are 
reported to be implicated in energy homeostasis, glucose, and lipid regulation in 
different biological systems. Distorted expression of those miRNAs is implied in 
metabolic syndromes and diseases. Elucidation of their role in adipose tissue
  
- 107 -
may provide opportunity for better diagnosis, prognosis, and therapeutic 
intervention of obesity, diabetes, and other metabolic disorders. 
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  3.5.4 Adipose-enriched miRNAs were implicated in 
inflammation  
 
Besides its function in metabolism, adipose tissues have emerged as an 
endocrine organ and an immune organ. Adipose tissues secrete and release 
hormones, cytokines, chemokines, and growth factors, which mediate and trigger 
inflammatory response and innate immunity (90). Obesity, which is a state with 
excessive accumulation of adipose tissue, is recognized as low-grade chronic 
inflammation (91).  
 
We thus set out to explore the function of adipose-enriched miRNAs in 
inflammation and immune-mediated disorders. First of all, we found that three 
major miRNAs which were induced by inflammatory conditions in previous 
published studies, including miR-21, miR-146 and miR-155, were enriched in 
adipose tissues (92). miR-21 was determined to be upregulated in psoriasis skin 
and asthma lung/leukocytes (92). miR-146 and miR-155 was both reported be 
increased in synovial fibroblasts and peripheral blood mononuclear cells in 
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rheumatoid arthritis patients. miR-146 also increased in psoriasis skin (92). Their 
high expression provided evidence to the inflammatory microenvironment of 
adipose tissues.  
 
Moreover, we found that expression of miR-146 and miR-155 was dependent on 
particular adipose depot and function, while miR-21 was ubiquitously abundant in 
all six adipose depots. miR-146 was more enriched in greater omentum and 
retroperitoneal adipose, while it has a relative low expression in upper layer and 
inner layer of back fat. miR-155 was more enriched in mesenteric adipose and 
was relatively low expressed in the other five adipose depots (Table 3.6). 
Adipose tissues, based on their anatomic location, are classified as SAT and 
VAT. SAT is found just beneath the skin while VAT is located in abdomen or 
surrounds vital internal organs such as stomach, liver, and kidney. Both types of 
adipose tissues are involved in metabolism; however VAT are emphasized for 
their role in inflammatory processes which precede the development of insulin 
resistance, type 2 diabetes and cardiovascular complications (93).  
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To conclude, we demonstrated that pivotal inflammation-induced miRNAs: miR-
21, miR-146, and miR-155 were all high abundant in adipose tissues compared 
to in muscle tissues. Based on further classification of SAT and VAT, miR-146 
and miR-155 were more enriched in VAT compared to SAT, while there was no 
discrepancy on the distribution and expression of miR-21 among different 
adipose tissues. 
 
  3.5.5 Adipose-enriched miRNAs were reported to be 
oncogenic and they shared common biological pathways with breast 
cancer overexpressed miRNAs 
 
Strikingly, a large portion (16 out of 29, besides the 3 let-7 family miRNAs) of 
adipose-enriched miRNAs were also overrepresented in various types of cancers; 
and their overexpression promotes cancer development, invasion, and 
metastasis, For instance, besides the well-known oncomiR miR-21, we found 
miR-103/107, which were overexpressed in gastric cancer and promoted cancer 
invasion and metastasis, were of high frequency in adipose tissues (94, 95). A 
list of adipose-enriched miRNAs which possess oncogenic potential in other 
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tissues and were determined to be of high expression in cancers was presented 
in Table 3.7.  
 
Instead of functioning individually, multiple miRNAs may work in a coordinate 
manner to regulate target genes in a common pathway (96, 97). Therefore, 
pathway enrichment analysis for a set of miRNAs rather than characterization 
individually will predict the global impact of them on pathways. To evaluate the 
putative affected pathways by adipose-enriched miRNAs, we carried out 
miRFocus pathway enrichment analysis.  The set of 32 adipose-enriched 
miRNAs were taken as input query. The majority of miRNAs, 28 out of 32, were 
associated with target genes, while 4 of them (miR-103a, miR-122, miR-320b, 
and miR-320d) were not predicted or verified with any target according to the 
database search. Particularly, the top three miRNAs with highest number of 
target gene annotations were let-7b, miR-200b, and miR-203 (664, 626, and 535 
target annotations, respectively) (Table 3.8).  
 
Eventually, by evaluating p-value generated from Fisher's exact test, 36 KEGG 
pathways were enriched for the set of adipose-enriched miRNAs (p<0.01). 
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Pathway enrichment analysis was also carried out on breast cancer over 
expressed miRNAs we identified by microarray study. The 22 breast cancer 
overexpressed miRNAs were subjected to pathway enrichment analysis (Table 
3.9). 36 pathways were enriched among the predicted targets from 32 adipose-
enriched miRNAs while 19 pathways were enriched from the 22 breast cancer 
overexpressed miRNAs (Table 3.9).  
 
Interestingly, we found that targets of adipose-enriched miRNAs shared a great 
portion of enriched pathways with those of breast cancer overexpressed miRNAs. 
Out of 19 pathways enriched from breast cancer miRNAs, 17 (~90%) pathways 
were also found enriched in adipose miRNAs. Unique pathways specifically 
enriched with adipose miRNAs were ErbB signaling pathway and insulin 
signaling pathway; whereas with breast cancer miRNAs, it was p53 pathway (89, 
98-101). p53 pathway serves to guard the cell cycle and its dysfunction leads to 
cell cycle dysregulation, tumor initiation, and progression (100-103). The ErbB 
pathway is recognized as oncogenic, controlling cell proliferation, survival, 
migration, and invasion; while a recent investigation demonstrated its novel role 
in regulating adipogenesis through ErbB2-FASN axis in adipocytes (99). Insulin 
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signaling pathway is of pivotal importance in glucose metabolism and lipid 
metabolism as well as in cell apoptosis, proliferation, and differentiation (104-
106). Essential biological pathways, for instance, MAPK pathway, TGF-β 
pathway, and neurotrophin pathway, were predicted to be affected by both sets 
of miRNAs (107-109) (Table 3.9).  
 
Overall, pathway enrichment analysis complements miRNA profile analysis and 
further serves as an innovative approach to discriminate miRNA expression traits 
and their global biological impacts under different biological systems. The 
similarity and discrepancy, on the pathway level, between adipose-enriched 
miRNAs versus breast cancer overexpressed miRNAs, suggested another 
potential access to explain the rise of obesity to cancer risk.  
 
Limitations of our pathway enrichment analysis included that we did not 
differentiate either tissue-specific gene expression/function or tissue-specific 
miRNA-target interactions between adipose tissue and breast cancer samples.  
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Table 3.7: Adipose-enriched miRNAs were reported to be oncogenic  
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Table 3.8: Putative target genes of adipose-enriched or breast cancer overexpressed 
miRNAs 
Putative target genes of adipose-
enriched miRNA 
Putative target genes of breast 
cancer overexpressed miRNA 
miRNA ID # of target genes miRNA ID 
# of target 
genes 
hsa-let-7b 664 hsa-miR-16 772 
hsa-miR-200b 626 hsa-miR-23b 645 
hsa-miR-203 535 hsa-miR-200b 626 
hsa-let-7c 527 hsa-miR-195 579 
hsa-let-7i 515 hsa-miR-200a 478 
hsa-miR-200a 478 hsa-miR-26a 448 
hsa-miR-130a 451 hsa-miR-107 435 
hsa-miR-107 435 hsa-let-7d 416 
hsa-miR-155 419 hsa-miR-301a 311 
hsa-miR-145 349 hsa-miR-21 281 
hsa-miR-148a 346 hsa-miR-425 122 
hsa-miR-152 340 hsa-miR-342-3p 86 
hsa-miR-21 281 hsa-miR-193a-3p 74 
hsa-miR-185 235 hsa-miR-324-5p 60 
hsa-miR-221 218 hsa-miR-345 55 
hsa-miR-143 179 hsa-miR-193a-5p 54 
hsa-miR-199a-3p 173 hsa-miR-191 40 
hsa-miR-199b-3p 173 hsa-miR-99a 28 
hsa-miR-146a 152 hsa-miR-663 23 
hsa-miR-140-3p 137 hsa-miR-615-3p 4 
hsa-miR-199a-5p 127   
hsa-miR-122 113   
hsa-miR-146b-5p 86   
hsa-miR-193a-3p 74   
hsa-miR-193a-5p 54   
hsa-miR-100 38   
hsa-miR-375 37   
hsa-miR-199b-5p 25   
Note: Number of target genes was estimated from those have been verified 
experimentally or those have been commonly predicted with 3 algorisms which were 
provided in method  
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3.6 Conclusion 
 
Altogether, we identified a set of adipose-enriched miRNAs after systematic 
screening of porcine adipose tissues. We found that adipose-enriched miRNAs 
were reported to play multiple roles in metabolism, inflammatory processes, and 
tumorigenesis.  The predicted targets of adipose-enriched miRNAs shared a 
great portion of KEGG pathways with those of breast cancer overexpressed 
miRNAs, which suggested a possible positive correlation between obesity and 
cancer risk on the level of signaling cascades. Particular target genes and 
biological function of adipose-enriched miRNAs await further thorough 
investigation. Our study provided opportunities to elucidate mechanisms 
underlying the molecular link between accumulated body mass (obesity), 
inflammation, and cancer at the miRNA level and highlighted the significance of 
miRNA functional investigation at the pathway level. Pigs, as an emerging model 
system, showed a high degree of conservation to humans based on miRNA 
sequences and expression patterns. Thus, the use of pigs as a model has great 
potential to benefit biological and medical research as well as therapeutic 
intervention.  
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_ 
Chapter 4: General Discussion and Perspective 
_ 
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My dissertation built up as my knowledge accumulated in the miRNA field. There 
is an on-going explosion of miRNA information nowadays. MiRBase version 18, 
which has been released in November 2011, contains 18,226 entries 
representing precursor miRNAs, that express 21,643 mature miRNAs in 168 
species. Compared to version 10, which was released in August 2007, the 
number of entries for miRNAs has increased 3 times.  
 
With the aid of high definition miRNA microarray, we are able to profile the 
expression of known miRNAs in a fast and convenient way. Newly developed 
next generation sequencing allows us to access the novel miRNAs as well as 
other non-coding RNAs, such as long non-coding RNAs and PIWI-interacting 
RNAs.  
 
Advanced technologies enable the high-throughput screening of miRNAome, 
even transcriptome, in our samples. However, the understanding of regulation by 
and of miRNAs, especially the in-depth characterization of each specific miRNA 
in a temporal and spatial manner, is lacking far behind. A variety of miRNA target 
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prediction tools have been established and published. Meanwhile, only a small 
portion, less than 1% of the targets have been experimentally verified.  
 
To study the consequences of excess endogenous prostaglandin E2 (PGE2) in 
prostate cancer cells (PC-3), I concurrently profiled miRNA and mRNA 
expression in the same context. Then with the combination of experimental data 
and computational target prediction, I identified putative miRNA-target mRNA 
pairs. Furthermore, I identified the candidate networks/pathways which may have 
been disturbed by the action of PGE2. This approach provided us a new access 
to determine putative miRNA:mRNA pairs and to better predict biological 
pathways affected by them.  
 
Another critical feature of miRNAs is that instead of functioning individually, 
multiple miRNAs may work in concert to regulate their target genes connected by 
common pathways. This feature enhances the challenges in miRNA functional 
study and emphasizes the need to evaluate their integrative function on the level 
of signaling pathways. Thus, in chapter 3, I applied miRFocus, an in-house 
developed web tool for miRNA pathway enrichment analysis, to better predict the 
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overall impact of a set of adipose-enriched miRNAs. From there, I was able to 
interpret which aspects the miRNAs may affect in a broader view.  
 
miRNAs have great potential to become diagnostic targets because of their 
temporal, spatial, and cell-type specific expression. Meanwhile, miRNA-based 
therapies, the most challenging and also the most active field, are under 
development by numerous pharmaceutical companies across the world. The 
main impediment to this progress is miRNA intracellular delivery, while the 
second difficulty is evaluation of miRNA-drug efficacy in human clinical trials. To 
date, quite a few miRNA-drugs are in preclinical stage and a miR-122 targeted 
drug, which can treat patients with Hepatitis C virus infection, has entered phase 
II clinical trial. It is hoped that by understanding and validating miRNA expression, 
their targets, and their function in different diseases, we can use miRNA-based 
drugs to conquer them.  
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